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Abstract 
Background: Tumour characteristics such as estrogen receptor, progesterone receptor and human 
epidermal growth factor receptor-2 status are routinely assessed using immunohistochemistry in all 
newly-diagnosed breast cancer patients. These biomarkers form part of the selection criteria used to 
determine the appropriateness of transcriptional gene profiling using MammaPrint, a 70-gene assay 
with level 1A evidence for chemotherapy selection in patients with early-stage breast carcinoma. This 
MammaPrint pre-screen algorithm does not include screening for pathogenic germline variants 
underlying differences in tumour pathology, increasingly considered to predict BRCA1/2-related cancer 
and response to PARP inhibitors that target the DNA repair pathway. 
Aim: The aim of this study was to determine whether one or more of the eight most common 
pathogenetic BRCA1/2 variants previously identified in the South African population are predictive of 
a MammaPrint high risk score. This investigation was prompted by detection of the BRCA2 c.7934delG 
founder/recurrent mutation in tumour DNA of a female patient diagnosed with bladder cancer four years 
after receiving a low-risk MammaPrint result. Next generation sequencing of her tumour DNA 
furthermore revealed genetic variation affecting cytochrome P450 2D6 (CYP2D6) enzyme activity 
associated with resistance to Tamoxifen, previously used by this patient together with anti-depressants 
that may inhibit enzyme function.   
Methods: A database query was performed to identify early-stage breast cancer patients referred for 
the MammaPrint test followed by CYP2D6 genotyping using the same pathology-supported genetic 
testing platform. A rapid point-of-care DNA assay was used to screen 50 DNA samples for eight 
BRCA1/2 founder/recurrent mutations: BRCA1 c.68_69delAG, c.1374delC, c.2641G>T, c.5266dupC 
and BRCA2 c.5771_5774delTTCA, c.5946delT, c.6448_6449insTA and c.7934delG.  
Results: The pathogenic BRCA2 c.7934delG variant was confirmed in the germline DNA of the index 
case with bladder cancer and was the only pathogenic variant detected in 10.2% of the study population 
(5/49, 1 sample failed). Two breast cancer patients with this pathogenic variant had a low-risk 
MammaPrint profile (2/25, 8.3%), while three patients with the same BRCA2 variant had a high-risk 
profile (3/24, 12%) for breast cancer metastasis. None of the other seven BRCA1/2 founder/recurrent 
mutations were detected in the study cohort. Patients with the BRCA2 c.7934delG founder/recurrent 
mutation was diagnosed at a significantly younger age than those without this pathogenic variant 
(p=0.02).  Intermediate (36%) and poor metabolizer (2%) status based on CYP2D6*4 genotype was 
detected in 18 of the 50 patients included in the study. Three of these patients also had the BRCA2 
c.7934delG founder/recurrent mutation, one with a low-risk (index case) and two with a high-risk 
MammaPrint recurrence risk profile.  
Conclusions: Our findings support use of the MammaPrint pre-screen algorithm to identify a subgroup 
of early-stage hormone receptor-positive breast cancer patients who may benefit from pharmaco-
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diagnostic BRCA screening as part of the MammaPrint service. Use of laboratory-based technologies 
can take several days or weeks from sample collection to report generation, posing a unique opportunity 
for rapid BRCA1/2 testing during the genomic counselling session. Delivery of a positive test result 
generated at the point-of-care, or a negative result requiring extended genome sequencing, are important 
considerations in clinical settings where loss to follow-up or access to gene-based cancer treatment 
remain a problem.   
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1.1.  Introduction  
The risk of death from non-communicable diseases (NCDs) such as cancer or cardiovascular disease 
(CVD) increases with advancing age in both men and women.  CVD is the leading cause of death in 
low- and middle-income countries, while in some higher income countries cancer deaths are twice as 
high compared to CVD (Bowry et al. 2015). Cancer is a complex disease involving multiple genes 
acting in combination with lifestyle and other environmental factors that may result in malignant 
transformation of cells. Some forms of cancer are associated with a family history of the disease, but in 
most instances no definitive pattern of inheritance is observed. This complicates dissection of genetic 
and environmental contributing factors and limits preventative strategies based on the causal pathways 
underlying cancer subtypes (Sas-Korczyriska et al. 2017).  
Approximately 1 in every 6 deaths are caused by cancer (Ferlay et al. 2019), with breast cancer 
recognised as the most common histologically diagnosed cancer in women. The incidence of breast 
cancer is steadily increasing in African women as they adopt a more westernised lifestyle, accompanied 
by altered reproductive cultures including delayed childbearing and smaller families, forgoing of 
breastfeeding, and diet changes that may lead to weight gain (Adeloye et al. 2018).  The increase in 
breast cancer incidence is reflective of the increased global incidence from 1.7 million in 2005 to 2.4 
million reported cases in 2015 (Fitzmaurice et al. 2017).  More than 8000 new breast cancer cases are 
reported in Africa every year, making up approximately 20% of all cancers (Brinton et al. 2014). These 
findings have established breast cancer as a leading cause of cancer among women globally, and South 
Africa is no exception. 
Poor survival and higher mortality rates reported in Africa are generally ascribed to late-stage 
presentation and a delay in diagnosis, which may partly be due to poor socio-economic status of the 
patient as well as sub-optimal health care systems (Espina et al. 2017). From studies conducted in Sub-
Saharan Africa more advanced breast disease is seen in patients living in rural areas compared to those 
in the urban centres (Elgaili et al. 2010; Kantelhardt et al. 2014). The stage as well as the age at which 
the diagnosis of breast cancer is made, vary between the different population groups living in South 
Africa, this could possibly be partly due to personal financial or psychosocial reasons (Friedman et al. 
2006). Geographic location has a significant effect on accessibility to medical centres (Vorobiof et al. 
2001). Lack of infrastructure and resources in rural areas and long-distances from centres of excellence 
where routine screening mammography are available contribute to the increased mortality in rural areas. 
Fear of dying from cancer or refusal of recommended medical treatment methods due to cultural beliefs 
are all factors affecting overall survival (Dickens et al. 2014). Conversely, where patients do agree to 
undergo therapy, the costs related to follow-up visits may be unsustainable for patients who have to use 
public transport services. 
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Due to the above-mentioned factors, breast cancer patients often decide not to continue with their 
treatment (Goudge et al. 2009). In addition to the financial burden, concerns about recurrence risk and 
therapy-induced co-morbidities are major stress-related factors associated with a diagnosis of cancer. 
Chemotherapy, hormonal therapy and radiation therapy, as well as some of the new targeted therapies 
such as poly ADP ribose polymerase (PARP) inhibitors targeting BRCA1/2 gene defects, can result in 
severe clinical complications. Chemotherapy overtreatment in early-stage breast cancer is of particular 
concern and raised an intense debate about the most appropriate way to identify patients at a sufficiently 
high risk of relapse to justify aggressive treatment (Michiels et al. 2016, Esserman et al. 2017, Tsai et 
al. 2018). Laboratory methods developed for this purpose include a 70-gene profile called MammaPrint 
(van’t Veer et al. 2002), a genomic decision-making tool with level 1A evidence for differentiating a 
subgroup of early-stage breast cancer patients with a low risk for distant metastasis from those 
experiencing metastasis in the first year after surgery (Cardoso et al. 2016). The magnitude of 
chemotherapy benefit found to be the highest in the first five years after diagnosis needs to be 
counterbalanced by the associated therapy-induced risks, including premature menopause, cardiac 
damage, cognitive dysfunction and leukaemia (Azim et al. 2011; Ramalho et al. 2017). 
Concerns about medication side effects such as bone loss associated with aromatase inhibitors and 
Tamoxifen resistance caused by variation in drug metabolizing enzymes (Baatjes et al. 2017, 2019; van 
der Merwe et al. 2012a, 2017), supports the application of germline genetic testing in conjunction with 
tumour gene profiling of hormone receptor-positive breast cancer using MammaPrint. Severe therapy-
induced hypertriglyceridemia due to the estrogenic effect of Tamoxifen on lipid metabolism may, for 
example, result in life-threatening pancreatitis (Singh et al. 2016). Deep vein thrombosis is also a 
common complication of malignancy, prolonged post-surgical immobility, and the effect of 
chemotherapy and endocrine treatment on the blood clotting cascade. PARP inhibitors recently 
approved by the Food and Drug Administration (FDA) for treatment of breast, ovarian and pancreatic 
cancer in patients with pathogenic BRCA1/2 variants, has furthermore been linked to severe deficiency 
of folate required as a co-factor in the DNA methylation process (Shammo et al. 2019). This finding 
highlighted the need for research to elucidate the mechanism of association between BRCA1/2 gene 
defects and the folate-homocysteine pathway also implicated in CVD.  
Breast cancer patients referred for diagnostic BRCA1/2 testing based on standard referral guidelines 
(Schoeman et al. 2013) may consider CVD multi-gene testing (Kotze and Thiart 2003; Kotze et al. 
2003) as part of the pre-screen algorithm developed for whole exome sequencing (WES) in genetically 
uncharacterised cases (van der Merwe et al. 2017). In this context, pathology-supported genetic testing 
(PSGT) of disease pathways shared by breast cancer and other NCDs (Kotze et al. 2013, 2015) provides 
a framework for combining diagnostic, prognostic and pharmacogenetic testing on the same platform 
(Figure 1).  This approach, first applied in the differential diagnosis of patients with familial 
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hypercholesterolaemia (FH) and less severe forms of dyslipidaemia (Kotze and van Rensburg 2012; 
Marais et al. 2019) are increasingly used to detect common risk factors shared between breast carcinoma 
and associated comorbidities (van der Merwe and Kotze 2018). Both FH and breast cancer have strong 
familial risk implications in South Africa due to founder effects and the major genes underlying these 
conditions can be screened for simultaneously in eligible patients using WES.  
 
Figure 1: A pathology-supported genetic testing (PSGT) framework for differential diagnosis of inherited and lifestyle-related 
breast cancer using a pharmaco-diagnostic exome pre-screen algorithm (EPA). BRCA1/2 founder/recurrent mutation testing 
is combined with assessment of common cardiovascular disease (CVD) risk factors to facilitate selection of genetically 
uncharacterised patients for whole exome sequencing (WES): 1) diagnostic BRCA1/2 testing is based on standard referral 
guidelines including early-onset breast cancer (<40 years), triple-negative breast cancer (TNBC), bilateral breast cancer, 
additional ovarian cancer, one 1st degree relative with breast or ovarian cancer, > 2nd degree affected relatives and male 
breast cancer in a relative (Schoeman et al. 2013); 2) Biochemical genetic testing using a CVD multi-gene assay is combined 
with CYP2D6 pharmacogenetics based on co-morbidities identified in patients treated with PARP inhibitors or hormone-, 
chemo- or immunotherapies; 3) genomic counselling is recommended based on treatment-induced comorbidities, drug failure 
and/or familial risk to determine the appropriateness of WES in genetically uncharacterized breast cancer patients 
[Reproduced with permission from van der Merwe and Kotze 2018]. 
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Genomic counselling is advisable in breast cancer patients with treatment-induced comorbidities, drug 
failure and/or familial risk to determine the appropriateness of WES or other next generation sequencing 
(NGS) technologies. The PSGT approach enables identification of high-risk patients eligible for WES, 
which in turn, enables extended analysis of disease susceptibility or drug metabolizing pathways 
implicated in genetically uncharacterised patients, using stored DNA sequence data that may in future 
become clinically relevant. CYP2D6 poor or intermediate metabolizers with pathogenic BRCA1/2 
variants will not gain the full benefit from Tamoxifen treatment and are therefore at higher risk of 
recurrence (Newman et al. 2008). This finding is of particular relevance in the South African population 
due to a founder effect responsible for the increased BRCA1/2 mutation frequency across ethnic groups 
(Reeves et al. 2004; van der Merwe and van Rensburg 2009; van der Merwe et al. 2012b), especially in 
hormone receptor-positive breast cancer patients using antidepressants that may inhibit CYP2D6 
enzyme activity (van der Merwe et al. 2012a).  The eight most common BRCA1/2 founder/recurrent 
mutations were recently incorporated into a rapid point-of-care (POC) assay 
(https://gtr.ukri.org/projects?ref=103993) applied for the first time in the present research study. The 
clinical impact of POC technology enabling rapid clinical decision-making at or near the site of care 
continues to grow with the shift from reactive to preventative medicine (Wang and Kricka 2018).   
1.2.  Modifiable and non-modifiable risk factors associated with breast cancer 
Based on epidemiological studies, there are multiple risk factors associated with development of breast 
cancer. Some are non-modifiable meaning that these risk factors cannot be altered by the individual 
(e.g. inherited genetic variants), while others are modifiable (e.g. BMI) and can be controlled to 
influence the risk of breast cancer. Modifiable risk factors are lifestyle and environmentally orientated 
and there is sufficient evidence that obesity is significantly associated with development of breast 
cancer, especially in postmenopausal individuals (Neuhouser et al. 2015).  Protani et al. (2010) found 
that among breast cancer survivors, obese women experienced poorer survival than those who were 
non-obese; however, clinical outcomes did not improve with weight loss after diagnosis (Protani et al. 
2010). Alcohol consumption increases the risk of developing breast cancer (Khan et al. 2010) as well 
as recurrence risk in postmenopausal and obese women (Ettinger et al. 2016).  
The risk of using hormone replacement therapy (HRT) in breast cancer development is complex and 
multifactorial (Hou et al. 2013). While the use of oral contraceptives may reduce the risk of colorectal 
and endometrial cancers, it increases the risk of breast cancer (Gierisch et al. 2013), as does a high BMI, 
also notable in premenopausal women (Cecchini et al. 2013). Pregnancy before the age of 30 and 
breastfeeding lowers breast cancer risk, while nulliparity increases the risk (Shapiro et al. 1971). 
Breastfeeding may be protective due to delayed return of regular ovulatory cycles postnatally, with an 
estimated risk reduction of 4.3% for every 12 months a woman is nursing (Shapiro et al. 1971). 
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Moderate exercise has been shown to infer a decreased risk of about 2% for development of breast 
cancer, while more regular activity is associated with a 5% reduction in risk (Wu et al. 2013). These 
findings may explain a proportion of the variation in the risk of developing breast cancer. 
The major non-modifiable risk factors are being female as male breast cancer accounts for less than 1% 
occurrence worldwide (Yalaza et al. 2016), and ageing given the fact that most breast cancers are 
diagnosed after the age of 50 years (DeSantis et al. 2014).  Menarche before the age of 12 and 
menopause after the age of 55 extends the time breast tissue is exposed to hormonal influence and 
therefore raises the risk. A family history of breast cancer, especially when diagnosed in first-degree or 
multiple relatives, increases risk, as does a personal history of atypical hyperplasia or carcinoma in situ 
of the breast. Radiation treatment (RT) to the chest area for other malignancies before the age of 30, 
especially if the women are left with intact ovarian function for ≥ 20 years post-RT, may increase the 
risk of breast cancer by up to 5 times (Cooke et al. 2013). Breast density is an independent risk factor, 
with the added disadvantage of not being able to differentiate a mass within the dense breast tissue, 
resulting in false-negative mammography (Boyd et al. 2011). 
A family history of cancer that may be caused by pathogenic gene variants in high penetrance genes 
such as BRCA1/2 predisposes women to hereditary breast-ovarian cancer (HBOC). BRCA1/2 and other 
high-moderate risk genes such as ATM, CDH1, CHEK2, PTEN, STK11 and TP53 accounts for 
approximately 25% of familial breast cancer and less than 10% of all breast cancers (Apostolou and 
Fostira 2013). Genetically predisposed individuals have a 10 to 20 times greater risk of developing 
breast cancer than those without pathogenic variants that may underlie diverse tumour molecular 
pathologies (Nagel et al. 2012), compared to women in the general population who carry a risk for 
breast and ovarian cancer of 12% and 1.3% respectively (Chen and Parmigiani 2007). Inherited 
pathogenic BRCA1 variants afford a lifetime risk of approximately 40% for ovarian and 80% for breast 
cancer, where the latter are generally found to be triple-negative breast cancers with early age of onset. 
Similarly, women with highly penetrant BRCA2 variants are confronted with a lifetime risk of 
approximately 20% for ovarian and up to 85% for breast cancer, where these tumours are usually 
hormone receptor-positive with features similar to non-BRCA associated breast cancer (Apostolou and 
Fostira 2013). Although relatively rare, breast cancer can also affect men with a risk of approximately 
6% in cases with pathogenic BRCA1/2 variants (Evans et al. 2010).  
With advancing NGS technologies, the mutational effects of other high penetrance cancer susceptibility 
genes were further substantiated, such as TP53 associated with Li-Fraumeni syndrome, PTEN mutations 
in patients with Cowden syndrome and STK11 associated with Peutz-Jeghers syndrome. Besides their 
association with developing hereditary breast cancer, these genes confer differing lifetime risks of 
developing these syndromes or cancer in individuals with pathogenic gene variants (Table 1).    
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Table 1:  Estimated lifetime risk of developing breast cancer associated with pathogenic variants in high penetrance genes 
with established clinical guidelines. 
Gene The lifetime risk of developing breast cancer 
BRCA1 40–80% 
BRCA2 20–85% 
TP53 56–90% 
PTEN 25–50% 
CDH1 60% 
STK11 32–54% 
Moderate penetrant variants are also increasingly detected in genes such as PALB2, CHEK2, BRIP1 
and ATM in families with breast cancer, accounting for approximately 3% of familial breast cancers 
(Nagel et al. 2012, Hollestelle et al. 2010, Goldgar et al. 2011). Population studies indicates that breast 
cancer susceptibility gene variants predominantly found in Polish breast cancer patients are PALB2, 
BRIP1, MRE11 and ATM (DeSantis et al. 2013, Podralska et al. 2018). These genes are normally 
responsible for maintaining genomic stability (Podralska et al. 2018). Notably, pathogenic germline 
variants in the CDH1 gene are associated with hereditary lobular breast carcinoma, but not (ductal) 
carcinoma of no special type (NOS) (Shrader et al. 2011). Moderate or intermediate-penetrance genes 
associated with hereditary breast cancer confer variable lifetime risks of developing breast cancer 
(Figueiredo et al. 2019) (Table 2).  Intermediate/moderate penetrant genes present a relative risk from 
1.5 to 5, for low-penetrant genes the risk is less than 2, while high penetrant genes are associated with 
a relative cancer risk of more than 5 (Apostolou and Fostira 2013).  
Table 2: Estimated lifetime risk of developing breast cancer associated with pathogenic variants in moderate penetrance 
genes. 
Gene Lifetime risk 
PALB2 20–40% 
CHEK2 25–37% 
BRIP1 Variable 
ATM 15–20% 
 
 
Low-penetrance risk variants can follow a multifactorial inheritance pattern influenced by lifestyle and 
other environmental factors. These include single nucleotide polymorphisms (SNPs) in the H19, 
TNRC19, MAP3K1, LSPL1, CASP8 and FGFR2 genes found to be significantly associated with breast 
cancer development (Li et al. 2011, Zheng et al. 2009, Cox et al. 2007 and Milne et al. 2010). While 
the clinical utility of low-penetrance variants in breast cancer is controversial, their use in a polygenetic 
risk score (PRS) may identify a subgroup of familial breast cancer cases not explained by a single gene 
defect. However, the clinical utility of polygenic risk scores will differ between population groups and 
disease subtypes such as ER-positive and -negative breast cancer. According to a study performed by 
Mavaddat et al. (2019), stratification of female patients according to clinical risk factors associated with 
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breast cancer together with the use of a PRS may facilitate improved breast cancer management. The 
study supports previous findings and suggested that a PRS might improve preventative screening 
programs (Mavaddat, et al. 2010). Evidence was also provided for incorporating tumour pathology into 
risk models to facilitate distinction between carriers of pathogenic and benign variants or functional 
SNPs underlying breast cancer subtypes amenable to precautionary intervention. Breast cancer risk 
stratification, taking modifiable and non-modifiable factors such as SNPs into account, may identify 
subsets of a population at greater risk who may benefit from a risk-reducing approach by altering 
modifiable factors (Maas et al. 2016). While these risk identifying and reducing approaches are 
important, findings from a study conducted in a rural context in South Africa reported that 69% of the 
participants had not heard of breast cancer before, only 5.3% ever had any kind of breast cancer 
screening performed, while holding the belief that they carried no significant risk factors for developing 
breast cancer (Ramathuba et al. 2015). These authors put forward recommendations of an educational 
intervention to enhance knowledge about breast cancer, the associated risk factors and symptoms as 
well as encouraging basic screening methods, such as breast self-examination (BSE).  
1.3. Breast cancer screening 
One of the most cost-effective screening methods to detect early breast cancer is to conduct a BSE, 
performed by assessing each breast for asymmetry or nipple discharges as well as feeling the breast to 
check for lumps or any thickened or swollen areas. Despite the ease of this self-administered test, 
women have to have some insight into breast health and cancer awareness to conduct a BSE and studies 
on the African continent report low percentages of women conducting these tests (Abay et al. 2018, Suh 
et al. 2012).  At a tertiary hospital in the Western Cape province of South Africa, 55% of interviewed 
women indicated that they regularly practised BSE (Moodley et al. 2018). 
The effectiveness of a BSE is debatable as the advantages in terms of reducing mortality has not been 
established (Loh et al. 2013). Most health professionals advise women to do regular BSE to familiarise 
them with their normal breast anatomy. The 2016 National Comprehensive Cancer Network (NCCN) 
guidelines endorse yearly clinical breast examination (CBE) for women of average risk after 40 years 
of age (Loh et al. 2013). Due to South Africa being a resource-poor region, a national mammography-
screening program is not currently in place and is mainly opportunistic or limited to symptomatic or 
high-risk patients in the public sector. The goal of breast imaging is to detect early malignancies and 
differentiate these from non-malignant breast disease.  
1.3.1. Mammography  
The first randomized control trials which compared periodic mammography screening with clinical 
examination confirmed a reduced mortality of roughly one third in the experimental group (Shapiro et 
al. 1971). The 2016 NCCN guidelines endorsed yearly mammography for women of average risk to 
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commence from the age of 40 years, with annual screens at 25 years of age for women who are identified 
at higher risk for developing cancer (Ettinger et al. 2016). However routine mammography can lead to 
needless stress and false-positive results, leading to unnecessary surgery with no reduction in mortality 
(Shapiro et al. 1971, Gøtzsche et al. 2013).  There is a growing awareness of a larger population of 
women for whom mammography has decreased sensitivity, notable in the younger age groups where it 
is most commonly due to dense breasts (Gøtzsche et al. 2013).  For this reason, these patients are 
screened using alternate technologies such as magnetic resonance imaging (MRI) and automated whole 
breast ultrasound (Kelly et al. 2010). Ultrasound is performed on pregnant women, patients younger 
than 30 years of age or for those who are lactating (Kelly et al. 2010). The increased detection of breast 
cancer by ultrasound following screening mammography suggests the added advantage of this 
technique for women with an average risk as well as high-risk patients with dense breasts (Berg et al. 
2008, Chae et al. 2013). MRI can be used for evaluation of inconclusive findings or where 
mammographic evaluation is limited, for example in patients with breast implants. Furthermore, MRI 
is useful for monitoring neoadjuvant chemotherapy treatment response as well as identifying the 
presence of minimal residual disease post lumpectomy. According to Lee et al. (2010), screening using 
both MRI and mammography can decrease the rate of mortality in breast cancer patients. Reidl et al. 
(2015) reported that MRI is effective in the detection of familial breast cancer irrespective of the 
patient's age or breast density. Furthermore, there is no added value in using mammography and 
ultrasound in patients who are screened using MRI (Kelly et al. 2010). MRI is the preferred screening 
method for cancer detection in healthy individuals with pathogenic BRCA1/2 variants (Buchanan et al. 
2018).  
1.3.2. Genetic counselling for risk evaluation 
Further investigations into breast cancer risk would require the services of genetic counsellors who are 
trained to identify patients with a strong family history of cancer who may benefit most from genetic 
testing in a family context.  Genetic services in South Africa, especially in rural areas, do not meet the 
genetic needs of the local population (Kromberg et al. 2012), where the responsibilities of counsellors 
are often carried out by other healthcare professionals who lack the formal specialized training 
(Gøtzsche et al. 2013). Inherited BRCA1 and BRCA2 mutations are identified respectively in about 52% 
and 32% of families where four or more members have breast cancer, while somatic mutations in these 
genes are rarely detected in patients presenting with sporadic breast cancer (De Silva et al. 2019).  
However, a negative family history or late-onset disease may eliminate a patient from testing and should 
not be the only criteria used for mutational analysis of BRCA1/2.  A study determining the prevalence 
of these mutations in sporadic breast/ovarian cancer patients showed a relatively high mutation 
detection rate (42.9%), including the identification of a de novo pathogenic BRCA1 variant in a patient 
older than 50 years of age (De Leeneer et al. 2012). 
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Research on the genetics of breast cancer in South Africa was initially focused on detection of 
pathogenic variants related to a founder effect, resulting in an increased frequency of certain BRCA1/2 
mutations in Afrikaners of European descent (Reeves et al. 2004). To date, at least eight pathogenic 
BRCA1/2 founder/recurrent mutations have been identified in the South African population across 
ethnic groups (Table 3) (Reeves et al. 2004, Sluiter and van Rensburg  2011, van der Merwe et al. 
2012b, Francies et al. 2015). The BRCA1 c.68_69delAG variant shares the same haplotype among 
Ashkenazi and Iraqi Jews characteristic of a founder effect but arose independently in several other 
population groups  due to recurrent mutational events (Bar-Sade et al. 1998). 
Table 3: BRCA1/2 founder/recurrent mutations associated with hereditary breast cancer in the South 
African population, with variants shown in brackets provided in the bank identifier code (BIC) format. 
Breast cancer patients have an approximately 17% increased risk of developing a second cancer 
(Molina-Montes et al. 2015). BRCA1/2 mutation carriers are more prone to multiple malignancies which 
may appear as either synchronous or metachronous. The former is defined as two or more primary 
malignancies coexisting at the time of diagnoses or develop within six-months period, and the latter as 
Gene Region dbSNP ID Number 
Nucleotide Change 
(HGVS Nomenclature 
Bold) 
Protein 
Change Population 
BRCA1 
NM_007300.4 
 
Exon 2 rs80357914  
c.68_69delAG 
[c.185delAG] p.Glu23Valfs European 
Exon 
11 
rs397508862 
 
 
c.1374delC 
[c.1493delC] p.Asp458Glufs Afrikaner 
rs397508988 
 
 
c.2641G>T 
[c.2760G>T] 
 
p.Glu881Ter Afrikaner 
Exon 
20 
 
rs80357906 
 
 
 
c.5266dupC 
[c.5382insC] 
 
p.Gln1756Profs European 
BRCA2 
NM_000059.3 
 
Exon 
11 
rs80359535 
 
 
c.5771_5774delTTCA 
[c.5999delTTCA] 
 
p.Ile1924Argfs Xhosa, Mixed 
Ancestry 
 
 
European rs80359550  
 
c.5946delT 
[c.6174delT] 
 
p.Ser1982Argfs 
rs397507858 
 c.6448_6449insTA p.Lys2150Asnfs Mixed Ancestry 
Exon 
17 
rs80359688 
 
 
c.7934delG 
[c.8162delG] 
 
p.Arg2645Asnfs Afrikaner, Mixed Ancestry 
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developing years after resection of the first primary cancer (Kim and Song 2015). In breast cancer 
patients, it is important to distinguish whether the contralateral or other lesion is metastatic or a second 
primary tumour. This distinction is not always clear (Kromberg et al. 2012). Chaudary et al. (1984) 
proposed criteria for the diagnosis of a second primary breast cancer in 1984 as follows: (i) there must 
be an in situ change in the contralateral tumour, (ii) the tumour in the second breast is histologically 
different from the cancer in the first breast, (iii) the degree of histological differentiation of the tumour 
in the second breast is distinctly greater than that of the lesion in the first breast, (iv) there is no evidence 
of local, regional, or distant metastases from the cancer in the ipsilateral breast (ipsilateral:tumor 
recurrence on the opposite breast). Despite recently developed novel methods such as cDNA 
microarray-based comparative genomic hybridization (CGH) that could be applied to assist in 
distinguishing a second primary cancer from the metastatic lesion, Chaudary’s criteria remains the most 
widely accepted to date. 
Additional features which could possibly influence the risk of a second cancer include age and lifestyle 
factors, such as body weight and alcohol intake, as well as subsequent tumour genetic alternations or 
the toxic effects of radiation and chemotherapy delivered during the course of the primary treatment 
(Sas-Korczyńska et al. 2017). Patients with primary malignant tumours should be meticulously 
followed up and counselling could provide risk assessment with suggested prevention strategies. All 
secondary tumours should be evaluated using histopathology and genetically profiled as the cancer 
genome often expresses differently in the metastasis, requiring different and targeted therapies (Mehdi 
et al. 2010).  
1.4.  Interventions relevant to the detection of pathogenic BRCA1/2 variants  
Patients who test positive for a pathogenic BRCA1/2 variant are faced with risk-reducing options which 
have a significant impact on their psychosocial wellbeing as well as the quality of life of their family 
members (Jeffers et al. 2014). Women may feel less feminine after risk-reducing surgical interventions 
have been performed, although it results in reduced anxiety about cancer risk (Gopie et al. 2013).  In 
high-risk individuals with pathogenic gene variants, risk-reduction surgery reduces breast cancer risk 
by 85% to 100% and breast cancer mortality rate by 81% to 100%, compared to patients without 
surgery. In BRCA1/2 mutation carriers, prophylactic oophorectomy may reduce the risk of ovarian, 
fallopian tube or peritoneal cancer by 80%, as well as significantly decrease mortality (Finch et al. 
2014). 
Although risk reduction and therapeutic options for patients with advanced disease are well-established, 
optimal management of early-stage breast cancer patients with pathogenic BRCA1/2 variants remain 
unclear. Sporadic breast cancer may require different adjuvant chemotherapy, even when pathological 
features are similar to BRCA1/2 associated breast cancer. The lack of benefit or response of hormone 
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receptor-positive breast cancer to adjuvant chemotherapy can be predicted by using multigene genomic 
assays such as the 70-gene (MammaPrint) or 21 gene (Oncotype DX) expression profiles that have the 
ability to generate a prognostic recurrence score (Cardoso et al. 2016; Sparano et al. 2019). Less 
favourable intrinsic factors are associated with pathogenic germline BRCA1/2 variants detected in 
patient referrals with hormone receptor-positive breast cancer (Shah et al. 2016). The use of NGS on 
tumour DNA extracted from cancer biopsies (solid or liquid) have promising capabilities of identifying 
the cause for underlying differences (Kanagal-Shamanna et al. 2014). Use of only 10 nanogram of DNA 
to perform NGS mutational profiling on cell blocks or fine needle aspiration cytological smears were 
shown to have high sensitivity to detect clinically relevant variants in the APC, ATM, CDKN2A, 
CTNNB1, FGFR2, FLT3, KDR, KIT, KRAS, MLH1, NRAS, PIK3CA, SMAD4, STK11 and TP53 genes 
than traditional platforms with high sample requirements.  
1.5.  Diagnosis and treatment of breast cancer subtypes 
Routine pathology testing is performed for all patients presenting with suspected breast cancer. This 
may initially be performed using fine-needle aspiration cytology, followed by a tissue biopsy often 
performed at mammography. Tissue biopsies are placed in fixatives and sent to a consulting 
histopathologist who confirms the diagnoses and type of breast cancer, as well as reporting on 
commonly used prognostic markers, including ER and PR, HER-2 and Ki-67 (Senkus, et al. 2015). 
The sex steroidal hormones are produced by the ovaries, and estrogen plays a significant role in the 
growth, development and differentiation of normal breast tissue as well as a stimulatory role in the 
development and progression of breast cancer. ER and PR are nuclear hormone receptors that act as 
transcription factors in breast epithelial cells. When attaching to their respective receptors, ER/PR 
stimulate the formation of proteins within the cell, which in turn influence the growth and function of 
breast cells (Tafe et al. 2014).  ER is overexpressed in about 70% of breast cancers and is evaluated 
microscopically in tumour samples using IHC staining. When the cells are found to express either ER 
or PR by a positive immunostaining reaction, the diagnoses of hormone receptor-positive breast cancer 
is made where either or both of these hormones are regarded as the key drivers of the malignancy. These 
cancers respond to the accompanying hormonal signals which enhace cellular proliferation and tumour 
growth. Hormonal or endocrine therapy is offered to these patients in the form of aromatase inhibitors 
or Tamoxifen, a selective estrogen receptor modulator (SERM). Depending on the risk profile, some 
patients are offered a combination of Tamoxifen and ovarian suppression, if they are premenopausal. 
However, in postmenopausal patients and when there is loss of ovarian function, aromatase inhibitors 
are prescribed as first-line endocrine therapy, which block the action of the enzyme aromatase in turning 
androgen into estrogen, effectively making less estrogen available (Awan and Esfahani et al. 2018). 
SERMs are drugs such as Tamoxifen and Raloxifene which act as antagonists in breast tissue, meaning 
that they interfere with the ERα transcriptional activity by blocking the physiological action of estradiol 
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and displacing it from ER, thereby mitigating the proliferative action of the hormone on the cancer cells. 
With impeded mitogenic activity, cells are unable to divide resulting in decreased tumour size as well 
as reducing the risk of cancer recurrence and distant metastasis (Keen and Davidson. 2003). 
Interestingly, Lui et al. (2014) have shown that Tamoxifen may induce apoptosis in ER-negative breast 
cancer cell lines via a novel mechanism of CIP2A-dependent p-Akt inhibition, which may partly explain 
why some ER-negative tumours respond to Tamoxifen treatment (Osborne. 1998). This finding 
suggests that Tamoxifen may induce other pathways related to anti-tumour activity. 
Aromatase inhibitors can affect the action of aromatase in fat, liver, and muscles, but cannot block the 
amount of aromatase present in ovaries. For this reason, the ovaries must be inactive for the therapy to 
be most effective (Słopień and Męczekalski 2016). Both aromatase inhibitors and Tamoxifen reduce 
estrogen levels, which impede cancer cell growth and can be used in the metastatic as well as the 
adjuvant setting. This treatment provides considerable benefit by reducing breast cancer recurrence and 
improving associated mortality in patients with endocrine responsive breast cancer (Kadakia and Snyder 
2016).  However, some breast cancers do not express any hormone receptors, may only express one of 
the two receptors or vary in the levels of expression from a strong to a weak immunostaining reaction.  
ER-positive tumours generally do not respond as well to chemotherapy as ER-negative breast cancer.  
Determining HER2 tumour status is an equally important prognostic and predictive factor. HER2 is a 
member of the epidermal growth factor receptors and a membrane tyrosine kinase involved in cellular 
growth and overexpressed in approximately 20- 30% of breast cancers. Malignancies which are found 
to be HER2 positive tend to be fast-growing, aggressive tumours with a high tumour grade. The HER2 
protein is expressed on the cell surface of normal breast epithelial cells and binds to growth factors 
which in turn stimulates cell division. Breast cancer tumour cells with a positive HER2 status have 
abnormally high levels of HER2 protein expression on their surface, resulting in increased proliferation 
with anti-apoptotic signals, which in turn drives tumour development and disease progression. 
Importantly, HER2 positive breast cancer responds to and can be treated with a targeted monoclonal 
antibody Trastuzumab (Herceptin), which binds to the HER2 receptor and reduces cellular replication 
and angiogenesis, and induces cell cycle arrest with an anti-tumour immune-response (Fiszman and 
Jasnis. 2011, Ross, et al. 2009). This has been shown to be effective in the adjuvant (Smith at el. 2007) 
as well as neo-adjuvant settings by shrinking and down staging breast cancer tumours (Goldhirsch. 
2013).  
1.5.1.  Routine laboratory assessment of hormone and HER2 receptor status  
As nuclear receptors, the ER and PR are commonly assessed using the Allred system of scorning, which 
is only performed on the invasive malignant tumour cells as ER/PR positive staining may be evident in 
the surrounding normal breast tissue as well. This system uses two scores based on the proportion of 
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positive staining cells (PS) in addition to the intensity at which they have stained (IS) (Qureshi and 
Pervez 2010). Proportion score classifies the percentage of the stained cells into six groups, where a 
score of zero indicates no staining and a score of 5 indicates that at least 67 to 100% of the cells are 
positive for hormone receptors (Table 4).  
Table 3: Allred scoring system based on the proportion of estrogen receptor (ER-positive stained cells. 
Score Percentage of stained cells 
0 ER-negative 
1 <1% cells are ER positive 
2 1-10% of cells are ER-positive 
3 1-33% of cells are ER-positive 
4 34-66% of cells are ER-positive 
5 67-100% of cells are ER-positive 
Score 0: no positive cells, score 1: < 1% of cells are positive, score 2: 1%-10% of cells are positive, score 3: 11-
33% of cells are positive, score 4: 34-66% of cells are positive and score 5: 67-100% of cells are positive. 
 
 
The intensity score (IS) categorises the staining intensity into classes, which are negative (0), weak (1), 
intermediate (2) or strong (3) (Qureshi and Pervez 2010). The final Allred score (AS) is calculated by 
adding the proportion score and intensity score, where 0 – 1 is regarded as negative and 2 – 8 as positive. 
A breast cancer tumour is regarded as hormone receptor-positive with any positive staining result for 
either ER, PR or both receptors. The potential benefit of hormonal therapy is reflected in increasing 
Allred scores (Table 5).  
Table 4:  Allred intensive scoring method for potential benefit from hormonal therapy. 
Allred score Effect of hormone therapy 
0-1 No effect 
2-3 Small (20%) chance of benefit 
4-6 Moderate (50%) chance of benefit 
7-8 Good (75%) chance of benefit 
 
 
To determine HER2 tumour status, breast cancer tissue is microscopically examined and scored from 0 
to 3 depending on the intensity of cell membrane IHC staining, where a score of zero or 1+ confirms a 
HER2-negative status.  An immunostaining score result of 3+ is regarded as a positive HER2 tumour 
status while that of 2+ is deemed equivocal and needs to be further tested by in situ hybridization (ISH) 
to confirm HER2 gene amplification. Although fluorescence in situ hybridization (FISH) is the most 
Page 28 of 98 
 
 
 
commonly used technique, other technologies include chromogenic or silver-enhanced ISH that are 
equally acceptable methods employed for confirming HER2 status. Chromogenic ISH uses a peroxidase 
enzyme labelled probe for visualisation while silver-enhanced ISH incorporates a silver-based detection 
on the same system. Advantages of the latter is that standard bright field microscopy can be used thereby 
avoiding the problem experienced with fading of fluorescent dye in the tissue samples.  FISH is a 
cytogenetic procedure that uses fluorescent probes to identify targeted DNA sequences in formalin-
fixed paraffin embedded (FFPE) tissue sections. The technique uses single-colour for the assessment of 
HER2 gene copy number per nucleus or a dual-colour assessment where chromosome 17 centromere 
and HER2 probes are differently labelled making the calculation of the HER2/chromosomal 17 ratio 
possible. Patients with ISH HER2/centromeric probe 17 (CEP17) ratio ≥ 2.0 or with a HER2 copy 
number > 6.0 qualify for anti-HER2 therapy. When HER2 ISH results are reported as equivocal, a reflex 
test should be requested and analysed on the same sample.  
 The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) first 
issued guidelines on ISH HER2 testing in breast cancers in 2007 and has since added revisions in 2013 
and 2018. These revisions are aimed at incorporating new knowledge to make the diagnosis of HER2 
more definitive, resolving clinical dilemmas that impact otreatment decision making, as well as an 
attempt to standardise laboratory testing procedures and reporting.   
1.5.2. Surrogate molecular subtyping 
The four major intrinsic/molecular breast cancer subtypes, luminal A, luminal B, HER2-enriched and 
basal-type, were originally described based on genomic microarray analysis (Perou et al. 2000). 
Following this discovery, less expensive IHC tests were shown to provide a reasonable approximation 
of these subtypes, based on expression of ER, PR and HER2. This pathology-only approach translates 
into categorising invasive breast cancer into luminal, HER2-positive, and triple-negative subtypes. 
These categories may be better approximated by incorporating proliferating index (Ki-67) 
immunostaining to determine the percentage of malignant cells that stain positive for this nuclear 
proliferative marker. Cancers expressing high levels of Ki67 tend to correlate with poor clinical 
outcome. When combined with results obtained from cytokeratin 5 and epidermal growth factor 
receptor (EGFR) markers, luminal tumours are stratified into luminal A and B subtypes, while triple-
negative tumours are separated from the basal-like subtype (Tang and Tse 2016).  IHC molecular 
classification is limited by lack of standardisation in terminology, use of biomarkers included for 
analysis and agreement on cut-off values for each IHC biomarker.   
Hormone and HER2 receptors as well as Ki67 assessment of FFPE breast cancer tumour specimens 
may be challenging to perform and standardise, while automated platforms such as the GeneXpert, 
using the Xpert Breast Cancer STRAT4 assay, may provide a less labour intensive method for 
assessment of these markers as well as faster turnaround time. This semi-quantitative real-time 
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polymerase chain reaction (RT-qPCR) based testing platform is used in research as well as clinical 
settings. The Xpert Breast Cancer STRAT4 assay enables qualitative measurements for ER, PR, HER2 
and Ki 67 mRNA from FFPE specimens and has been shown to correlate well with central IHC/FISH 
tumour testing (Wu et al. 2018). The samples need to be prepared by an experienced anatomical 
pathologist to ensure suitable FFPE material for assessing the mRNA levels of ESR1, PGR, ERBB2, 
and MKi67. The reference gene, CYFIP1, serves to verify specimen adequacy and is used to normalise 
mRNA expression levels of the four genes analysed simultaneously in the kit. Breast cancer FFPE tissue 
samples are prepared as tissue sections on glass slides and treated with a lysis kit prior to use. Once the 
tissue lysate has been prepared, an aliquot is placed into the appropriate sample chamber in the assay 
cartridge and placed into the GeneXpert instrument for processing. A probe check control (PCC) is used 
to verify reagent rehydration, real-time PCR tube-filling in the cartridge, probe integrity and dye 
stability. In total, the assay utilises six fluorescent channels for target or control detection in a distinct 
channel with its own detection cut-off parameters for target detection. The GeneXpert instrument 
consists of a barcode scanner and a personal computer with preloaded software for performing the test 
and viewing the results.  
The purpose of molecular or IHC sub-typing is to identify the likely outcomes for each patient. Breast 
cancer patients with luminal type tumours are ER/PR-positive, respond well to endocrine therapy and 
have a favourable prognosis (Parise et al. 2014). Endocrine therapy is generally prescribed for luminal-
type tumours, where pre-menopausal women are offered Tamoxifen and post-menopausal breast cancer 
patients are usually advised to use aromatase inhibitors. Breast cancer patients with luminal B tumours 
are more often diagnosed at a younger age than those with luminal A tumours and tend to have a poorer 
prognosis.  Basal-type breast cancers are usually triple-negative tumours (ER-, PR-, and HER2-) and 
are mostly detected in younger women. These tumours display an aggressive immunophenotype and 
have a poorer prognosis when compared to the luminal A and B subtypes. A subgroup of HER2 positive 
tumours is reclassified by genomic testing as HER2-enriched, with a tendency to be lymph node-
positive at diagnosis. On a DNA level, HER2-enriched tumours demonstrate the highest number of 
mutations expressed in the genome, with 73% and 39% of these tumours found to be PIK3CA and TP53 
genetically altered, individually. Although 68% of HER2-positive tumours show HER2 overexpression, 
identification of HER2-enriched subtypes among HER2-negative breast cancer may occur when more 
genes are analysed beyond the limitations of single-gene IHC (Roberts et al. 2013). HER2-positive 
disease is caused by the amplification the HER2 gene which leads to uncontrollable cell growth and has 
a higher recurrence rate than HER2-negative tumours (Slamon et al. 2011). They show poor tumour 
grading and are diagnosed at a younger age compared to the luminal A and B subtypes. Anti-HER2 
treatments such as Herceptin are more effective in breast cancer patients with the HER2-enriched 
compared with luminal B HER2-positive tumours (Ross et al. 2009, Myburgh et al. 2016). 
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1.5.3. Molecular subtyping using microarray analysis 
Breast cancers are classified as luminal on histopathology when found to be ER+/HER2-negative. 
However when using the 80-gene BluePrint assay for molecular subtyping, a subset of these tumours 
can be reclassified as ER+/basal, high genomic recurrence risk tumours (Whitworth et al. 2017). Once 
reclassified, these ER+/basal cancers show a significantly higher pathologic complete response (pCR) 
compared to ER+/luminal A or B molecularly classified tumours, while displaying a similar pCR to 
ER-negative/basal patients in the neoadjuvant setting (Groenendijk et al. 2019). Reasons for this 
reclassification may be due to borderline ER positivity on routine assessment, or the inability of IHC 
or mRNA to separate functional ER from non-functional ER as many ERα variants are present in human 
tissue displaying varying degrees of activity. For this reason, genomic risk assessment using the 70-
gene assay or the 21-gene assay will not identify this group of clinically relevant patients, which can be 
classified by addition of the molecular subtyping 80-gene signature, BluePrint.  
The value of combining MammaPrint with BluePrint was demonstrated in South African patients with 
early-stage breast cancer based on the following findings of Grant et al. (2019): 1) Neither IHC nor 
single-gene genomic mRNA reporting of ER/PR status can replace the combined use of these two tests 
for molecular subtyping; 2) Reliable distinction between luminal A and B type tumours is not possible 
using IHC or single-gene ER/PR/HER2 genomic mRNA assessment; 3) IHC combined with microarray 
gene profiling enables the identification of endocrine treatment resistant ER/PR-positive tumours 
lacking ERα function (basal-like), despite positive expression at the protein and single-gene RNA level. 
Several studies reported that the 21-gene breast cancer recurrence score has value in ER+/HER2 
negative breast cancers, but may contribute similar information to that received from more cost-
effective histopathological reports and surrogate molecular subtyping tools, including novel 
nomograms which use the commonly reported clinicopathologic variables (Orucevic et al. 2017).    
Determination of ER, PR and HER2 status forms part of the MammaPrint pre-screen algorithm (MPA) 
developed as a cost-saving strategy for microarray gene profiling in South Africa (Grant et al. 2013), in 
a similar way that eligibility for BRCA1/2 screening may be based on age of onset and family history 
(Schoeman et al. 2013). Subsequent studies performed in the UK and USA (Slade et al. 2016; Sun et 
al. 2019) demonstrated a cost-effective implementation of inherited cancer screening in unselected 
breast cancer patients when BRCA1/2 testing is performed as an integral part of oncology practice. This 
finding raised the possibility that use of the pathology-supported genetic testing (PSGT) platform 
(Figure 1) to incorporate germline genetic testing for patients referred for the MammaPrint test may 
improve clinical management in a subgroup of high-risk patients that may not otherwise be considered 
for BRCA1/2 gene screening. 
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1.6.  Pathology-supported genetic testing  
Irrespective of whether a patient presents with a risk of cancer development or with a nodule suspicious 
of breast cancer, the clinician is required to perform a clinical assessment and interpret these findings 
in the context of the personal and family history. Unsuitable or irrelevant testing needs to be avoided 
and only that which is deemed necessary and able to add preventive, diagnostic, prognostic or 
therapeutic value should be conducted after this initial assessment. If breast cancer is suspected, a tissue 
biopsy is required for histopathological confirmation, and by combining the results of the 
clinicopathological parameters a cancer management strategy is developed for the patient. Although the 
pathology report may not always allow a clear clinical decision on the use of adjuvant chemotherapy, 
it provides the basis for identification of the need for tumour genomic testing. Inappropriate use of the 
MammaPrint test can be avoided by using the PSGT approach described by Grant et al. (2013, 2019). 
By combining recurrence risk assessment using MammaPrint with molecular subtyping using 
BluePrint, additional information not provided through routine pathology testing and germline genetic 
testing is obtained on which to base anti-cancer therapy (Figure 2). Tumour gene expression profiling 
and NGS is used to determine the underlying breast cancer biology, which in turn assists decisions 
regarding chemotherapy use and more accurately suggest use of targeted agents such as Herceptin 
aimed at interrupting the active pathways within the tumour genome. Germline DNA testing may 
furthermore improve clinical outcome by identifying potential therapy-related risks associated with 
genetic variation in drug metabolizing enzymes such as CYP2D6, which is associated with Tamoxifen 
resistance. In Tamoxifen-treated patients who have experienced relapse, metastatic or metachronous 
malignancies, despite being classified with low-risk tumours by genomic profiling, CYP2D6 
genotyping or concomitant medication affecting enzyme activity may provide an explanation for poor 
clinical outcome. Patients referred for genomic tests such as MammaPrint, BluePrint or OncoType DX 
may also benefit from BRCA1/2 testing regardless of the lack of family history, as such cases could be 
offered alternate or additional targeted therapies such as PARP inhibitors. Clinicians should be 
encouraged to use the opportunity to advise screening for other family members at risk of developing 
breast cancer or other BRCA related malignancies.    
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Figure 2: Schematic diagram illustrating the concept of pathology-supported genetic testing (PSGT) where routine clinical 
and pathology reports are evaluated to determine the appropriateness of breast cancer genetic/genomic testing. The PSGT 
approach incorporates multiple assay platforms to facilitate improved quality assurance on which to base treatment decisions. 
Clinical observations and family history identify the need for germline testing of individuals at risk of developing breast cancer, 
therapeutic risk or not gaining optimal benefit from certain drugs used in the treatment of endocrine positive breast cancer. 
In cases of therapeutic failure, BRCA1/2 testing may reveal pathogenic variants in cases who could be offered alternative 
therapies to improve outcomes or risk reduction of developing metachronous malignancies. Genetic screening of family 
members is advised to prevent them from developing BRCA1/2 related cancers.  
Use and improvement of the PSGT platform has been a focus of breast cancer research since the 70-
gene MammaPrint microarray test became available in South Africa, following FDA approval in 2007. 
Development of local referral criteria led to reimbursement of the MammaPrint by medical schemes in 
South Africa (Grant et al. 2013). An important requirement was to establish a sustainable breast cancer 
genomics database (accessible to registered users at www.gknowmix.org) for monitoring of clinical 
outcome and ongoing comparative effectiveness studies (Grant et al. 2019). 
Patient presenting with familial risk or suspected breast 
cancer  
Clinical evaluation including 
mammography/ultrasound/MRI
Pathology testing
Clinician interprets in context of  family and patient history 
Relies on clinco-pathological results to select appropriate genetic tests 
Patient without cancer:
Germline DNA testing for known
BRCA1/2 variant in family
Monitoring
Prophylatic treatment
Patient with cancer:
Tumour RNA genomic profiling:
Chemotherapy and/or Endocrine 
therapy
Molecular  subtyping
Luminal/HER2 enriched/Basal type
Relapse/metastasis reported 
results in further testing
Next Generation sequencing
identify targeted therapeutic agent
CYP2D6: Drug metabolizer status
BRCA1/2: Pathogenicity
Cancer prevention through family 
screening
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Traditional clinicopathological factors assessed in all newly diagnosed breast cancer patients, such as 
age, number of positive axillary nodes, tumour size, grade, ER, PR, HER2 and Ki67 status, are 
important for prognostic reasons and hold important therapeutic implications. However, patients with 
similar clinicopathological characteristics may experience remarkably different disease outcomes, 
indicating the inability of these standard indicators to fully explain the biological complexity of or 
accurately reflect the heterogeneity of breast cancer. In this context, genomic technology has advanced 
our understanding of genetic variation in tumour gene expression and driver mutations.  
The use of adjuvant systemic therapy has resulted in a steady decrease in breast cancer mortality. 
Neoadjuvant chemotherapy may be administered before surgery to shrink the tumour in situ, affording 
more surgical options. Adjuvant chemotherapy is administered after breast cancer surgery and is 
intended to prevent recurrence of the disease, particularly distant recurrence (Rampurwala et al. 2014). 
Chemotherapy may also be suggested when patients with invasive breast cancer have unfavourable 
prognostic factors, or if there is spread to nearby lymph nodes.  Although the use of these 
chemotherapeutic treatments has demonstrated improved survival, not all patients benefit from it. 
1.7.  MammaPrint  
Many patients with early-stage breast cancer suffer side effects of chemotherapy without optimal 
benefit, while increasing the economic burden on health care. MammaPrint allows accurate distinction 
between patients at low and high risk of developing distant metastases and could identify those patients 
most likely to benefit from adjuvant therapy (van de Vijver et al. 2002, Buyse et al. 2006). Breast cancer 
patients classified as high risk for recurrence was shown to have a less than 50% chance of survival 
after 10 years and less than 44% chance to be metastasis-free after 10 years without adjuvant treatment. 
In comparison, patients classified as low risk of recurrence had a 97% chance of survival after 10 years 
and 87% chance to be metastasis-free after 10 years without adjuvant treatment. Brieast cancer patients 
with a poor prognosis profile based on the 70-gene MammaPrint assay were shown to benefit from 
administration of chemotherapy (Straver et al. 2010). Although several multi-gene assays are 
commercially available for assessment of recurrence risk in early-stage breast cancer patients, 
MammaPrint is the only test to date that have both been cleared by the FDA and awarded level 1A 
clinical utility evidence for chemotherapy benefit in early-stage breast cancer patients with up to three 
nodes involved. The FDA does not evaluate tests for clinical utility, only for analytical and clinical 
validity which is based on the prognostic value in the case of MammaPrint  (Slodkowska et al. 2009). 
Several retrospective studies have shown that MammaPrint can predict that patients with a low-risk 
gene profile can safely avoid chemotherapy. Mook et al. (2010) explored the use of the 70-gene assay 
to predict clinical outcomes in breast cancer patients with lymph node invasion. The study showed that 
the 70-gene assay is expressively superior to histological grading, ER status prediction, and to lymph 
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node invasion. The authors recommended the use of MammaPrint in patients with node-positive breast 
cancer. Whitworth et al. (2017) compared MammaPrint/BluePrint intrinsic subtyping with clinical 
IHC/FISH subtyping in clinical luminal breast cancer patients to predict treatment sensitivity. This 
study revealed that there was a pathological complete response for clinical luminal patients to 
neoadjuvant chemotherapy, with reclassification of approximately 20% patients by the BluePrint test 
to the basal subtype type.  
The MINDACT (Microarray In Node negative Disease may Avoid Chemotherapy) trial was a 
prospective, randomised, phase III controlled clinical trial, designed in 2005 to assess the clinical utility 
of the MammaPrint genomic assay. The trial demonstrated that the patients who were considered high 
risk based on traditional and clinical-pathological features, but have a low-risk genomic signature and 
did not receive adjuvant chemotherapy, had a 5-year distant metastatic free survival rate of at least 92% 
or more (Cardoso et al. 2016).  It was concluded that chemotherapy may not be required in about 46% 
of women diagnosed as clinically high-risk, early-stage breast cancer. The results of the MINDACT 
trial provides the highest level of evidence to support the use of MammaPrint as an accurate breast 
cancer assay in a subset of clinically high-risk patients.  
Conventional histopathological subtyping of breast cancer tumours using IHC and FISH has limited 
reproducibility and accuracy and cannot determine intrinsic molecular subtypes accurately. The 
BluePrint molecular subtyping profile determines the mRNA levels of 80 genes that best discriminate 
between luminal A and B breast cancer subtypes, HER2 enriched and basal-type. Each of these 
genetically determined intrinsic subtypes has marked differences in long-term outcome and response to 
chemotherapy. The BluePrint assay was validated using four independent validation cohorts including 
784 patients studied and offers a further stratification of the luminal subgroup into types A and B when 
used in combination with MammaPrint, which is critical in determining the need for chemotherapy 
(Whitworth et al. 2014). Patients with the luminal A molecular subtype can avoid chemotherapy while 
patients with a MammaPrint high-risk profile are equivalent to luminal B and may be offered 
chemotherapy (Whitworth et al. 2014). HER2-enriched is one of the four main molecular subtypes of 
breast cancer that can further be stratified by the 80-gene BluePrint profile as a valuable addition to the 
70-gene MammaPrint profile (Whitworth et al. 2014). Although several prognostic and predictive tests 
have been approved for clinical use, their translation into routine clinical practice is not straight forward 
and requires processing and interpretation at specialised facilities.    
1.8.  Limitations to predict tumour response to any specific anticancer agent 
Many pathology tests used in clinical practice have limited ability to predict tumour response to a 
specific anticancer agent. With improved genomic microarray or NGS analyses, it is possible to more 
accurately predict potential benefit of therapy targeted at the individual tumour biology. Biomarkers 
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can be used to assist in clinical decision making by identifying the most appropriate therapy targeted to 
a particular cancer. In cases where the application of traditional clinicopathological risk factors or 
genomic profiling tools such as MammaPrint reflected a low risk for breast cancer recurrence, and 
patients did not receive chemotherapy, it may also help to explain drug resistance and why a small 
number of breast cancer patients relapse. In order to effectively treat metastatic tumours based on 
molecular alterations which may not have been present in the primary tumour, tumour DNA could be 
sequenced for identification of actionable gene targets (Bombonati et al. 2011). The aim is to identify 
specific mutational events expressed in metastatic breast cancers in an attempt to match and personalise 
treatment plans. Biomarkers can be used to assist in clinical decision making for selection of the most 
appropriate therapy targeted to a particular cancer.  
Several NGS applications with varying degrees of evidence have become commercially available over 
recent years. One of these tests offered to South African patients called OncoDEEP, combines NGS 
with IHC tailored to a specific cancer in order to identify treatment targets at both the protein and tumour 
DNA level. An international study published by Laes et al. (2018) on the performance of this integrated 
approach includes South African data from breast and other solid cancers. A combined genomic 
assessment allows for the complete profiling of the tumour and tailors the matching treatment to target-
specific immunotherapy and chemotherapy. However, the clinical utility of NGS results reported to the 
ordering clinician and the extent to which different genomic applications compare with each other 
remains largely unknown. A key issue in clinical oncology practice is the ability to accurately interpret 
pharmacogenomic reports in order to distinguish clinically meaningful results from those that are not 
actionable. Treating clinicians have time constraints and require concise reporting of clinically relevant 
results that may be considered by some as an elusive target due to the ever-changing cancer genomics 
landscape. 
In a study by Weiss et al. (2015) using the Foundation One (F1) and Paradigm Cancer Diagnostic 
(PCDx) tests on FFPE tumour tissue of 21 cancer patients, genomic data generated by different 
laboratories using the same samples were compared. The F1 test returned information on chromosomal 
abnormalities, somatic mutations, insertion and deletion polymorphisms, and DNA copy number 
variants at approximately 250 times coverage, while PCDx generated similar data at a much higher 
(5,000x) coverage, in addition to mRNA expression levels. Differences in turnaround time (TAT) was 
noted as one of the most important considerations for patients with progressing metastatic cancer; the 
longer the delay in initiating treatment the shorter the window of opportunity to change the disease 
course. A higher percentage of clinically relevant actionable targets were reported with the PCDx assay 
using the Ion PGM sequencer in relation to commercially available drug or clinical trial drugs, with 
some discrepancies noted. KRAS and ERBB2 variants were missed by PCDx as the gene regions 
spanning these specific alterations were not included in the platform at the time of the study. However, 
the resulting categorization for PCDx was the same as F1 since none of the mRNA targets indicated 
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available commercially or clinical trial drugs at the time of the study. Conversely, elevation of TOP2A 
mRNA confirmed clinical actionability through expression studies. These contrasting findings raised 
questions about variants detected in tumour DNA when there are no indication of protein expression of 
the relevant biomarkers, which could be misleading.  Addition of an expression measurement to NGS 
platforms is therefore important to identify clinically relevant treatment targets. Indeed, after the results 
of Weiss et al. (2015) had been published, both the KRAS and ERBB2 variants were added to the PCDx 
platform in addition to several actionable IHC biomarkers, including AR, ER, HER2, MET, MGMT, 
PTEN, PR, TOP1, TYMS, PD-L1, and PD-1. In this comparative study, clinically relevant actionable 
targets were identified in 47%–67% of diverse cancer types at a total charge of US $4,800 for PCDx to 
medical insurance, versus US $5,800 for the F1 test per sample. To improve cost-effectiveness, the 
following selection criteria were defined as appropriate for tumour NGS at the time: 1) stage 4 solid 
tumor with 2) progression on at least one line of standard therapy, or 3) no standard of care available 
for the type of cancer diagnosed.  
The pathology of breast cancer may not only affect the decision about tumour DNA or RNA analysis, 
but also germline genetic testing. ER/PR status was an important consideration for development of a 
clinical pipeline used to identify the target population most likely to benefit from aromatase inhibitors 
or tamoxifen pharmacogenetics in South African breast cancer patients (Baatjes et al. 2017).  Targeting 
genetic/genomic testing to individuals with a high chance for a positive result improves the likelihood 
of demonstrating cost-effectiveness and overall clinical utility of new molecular technologies.  
1.9.  From tumour to germline genetics    
The clinical utility of the MammaPrint microarray for assessment of metastatic potential (Cardoso et 
al. 2016), and single-gene BRCA1/2 mutation testing of tumour or germline DNA as a treatment target 
for PARP inhibitors (Dziadkowiec et al. 2016) or to assess risk for familial breast cancer (Møller et al. 
2014), is well established. However, the use of NGS on tumour DNA extracted from breast biopsies 
(solid or liquid) for targeted therapies requires further research (Cummings et al. 2016). The clinical 
utility of CYP2D6 genotyping for determination of Tamoxifen resistance is, for example, less clear than 
the pharmacogenetic effect on response to anti-depressants, which led to an implementation study in 
South Africa (van der Merwe et al. 2012a). This translational research performed in breast cancer 
patients considered for concomitant treatment with Tamoxifen and antidepressants that may inhibit 
CYP2D6 enzyme function, increased the awareness of clinicians about the potential benefits of multi-
gene testing to facilitate prevention of cumulative risk (Baatjes et al. 2017).  
Detection of bilateral breast cancer or multiple primary tumours in a patient increases the probability of 
hereditary disease. NGS systems capable of analysing massive amounts of sequencing data at the same 
time are increasingly used to screen breast cancer patients for causative gene variants and 
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pharmacogenomic markers. The differences between NGS platforms lie mainly in the technical details 
of the sequencing reactions and can be categorized into four groups, namely pyrosequencing (Qiagen 
Pyromark Q24 - Pyrosequencing analysis system), sequencing by synthesis, or by ligation 
(Illumina HiSeq 2000 sequencing machine), and ion semiconductor sequencing (Ion Torrent Personal 
Genome Machine) (Van Dijk et al. 2014).  
Third-generation nanopore sequencing technologies such as MinION use a portable device for analysis 
of long-range DNA and RNA fragments in real-time. The MinION sequencing device is capable of 
reading more than 100Kb and has been used in field laboratory work to analyse samples as small as 
viruses or as large as the whole human genome (Jain et al. 2016). Nanopore long reads simplify the 
assembly and repetitive regions, also improving the speed of species identification in experiments. The 
MinION is the world first POCket-sized device that offers ultralong read length sequencing in real-time 
at a relatively low cost.  
A study performed by Liau et al. (2019) showed that nanopore sequencing offers a high throughput 
method for detection of both known and new pharmacogenetic variants, including duplicated alleles. 
Due to the long reads generated by nanopore sequencing, accurate CYP2D6 haplotyping can be 
achieved without the need for statistical phasing, as also reported previously (Ammar et al. 2015). This 
third-generation sequencing technology was also used to accurately categorise in-frame and out-of-
frame splicing events after sequencing of whole BRCA1 mRNA transcript sequencing (de Jong et al. 
2017). Massive parallel sequencing for identification of BRCA1/2 variants are usually performed on 
NGS platforms such as the llumina MiSeq and Ion Torrent, followed by Sanger sequencing considered 
the ‘gold standard’ for confirmation of BRCA1/2 or other variants (Toland et al. 2018). Further studies 
are needed to determine whether MinION nanopore sequencing can replace multiplex ligation-
dependent probe amplification (MLPA) as the method of choice for identification or confirmation of 
large rearrangements including duplications and deletions in BRCA1/2 or other cancer-related genes. 
1.9.1. BRCA1/2 testing at the point-of-care   
The two major breast cancer susceptibility genes, BRCA1 and BRCA2, help protect against the 
development of tumours by acting as tumour suppressors that regulate cell division and repair DNA 
damage that can lead to uncontrolled cell growth. A pathogenic BRCA1/2 variant can affect the ability 
of the affected genes to perform functions such as DNA repair and recombination. With recent 
development of the ParaDNA POC System using HyBeacon probes to detect the eight most common 
BRCA1/2 founder/recurrent mutations (https://gtr.ukri.org/projects?ref=103993) previously described 
in South Africa (Reeves et al. 2004; van der Merwe and van Rensburg 2009; van der Merwe et al. 
2012b), rapid DNA testing can now be performed as a stand-alone test or incorporated into the PSGT 
algorithm.  
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HyBeacon probes can process samples at a rapid pace using extracted DNA or crude saliva, swab, urine 
and blood samples (Howard et al. 2011). Within approximately 60 minutes, the POC diagnostic tool 
performs PCR amplification and analysis of the sample, while not taking more than 15 minutes to set 
up the instrument (Blackman et al. 2015).  A summarised result is generated automatically and 
visualised via an attached laptop. Successful application of POC testing in a clinical setting was first 
demonstrated for genotyping of CYP2C9*2, CYP2C9*3 and VKORC1 related to differences in the 
ability to metabolise Warfarin (Howard et al. 2011).   This pharmacogenetics POC assay using 
HyBeacon probes produced excellent and accurate results for dosage monitoring for patients on 
anticoagulant therapy. In a subsequent implementation study of genotype-guided dosing of the oral 
anticoagulant, successful integration of POC genetics was demonstrated in a clinical setting in the UK 
(Jorgensen et al. 2019).  A similar process is required in South Africa for implementation of BRCA1/2 
founder/recurrent mutation testing, as explored in breast cancer patients referred for the MammaPrint 
test or NGS of tumour DNA in the present study. 
 
Compared to other genomic assays such as Oncotype DX (Shah et al. 2016), the MammaPrint test has 
not previously been studied in BRCA1/2 mutation carriers or cytochrome P450 2D6 (CYP2D6) 
intermediate and poor metabolizers (Ross et al. 2008). Cytochrome P450 is a superfamily of enzymes 
expressed in the liver and some areas of the central nervous system, with CYP2D6 identified as one of 
the most significant enzymes responsible for the metabolism of medication in the human body (Samer 
et al. 2013). Van der Merwe et al. (2012a) highlighted the fact that CYP2D6 genotyping may be of 
particular relevance for prevention of cumulative risk in BRCA2 breast cancer patients who receive 
Tamoxifen, or antidepressants known to inhibit enzyme function (Newman et al. 2008).  However, it is 
uncertain whether BRCA1/2 mutation screening and CYP2D6 genotyping could add value to the PSGT 
approach when applied in the MammaPrint service in South Africa (Grant et al. 2013). This research 
question was addressed in the present study based on the knowledge that an integrated analysis of 
germline and tumour genetics may facilitate the identification of signal pathways and genetic alterations 
underlying biological changes with different treatment requirements (Kalia 2015).  
 
Use of a single platform that brings together fragmented pathology and genetic data facilitates improved 
quality assurance on which to base treatment decisions (Figure 3). The relatively long turn-around time 
(2-3 weeks) of complex genomic tests performed on genetic material extracted from tumour biopsies 
(RNA/DNA) creates an opportunity for evaluation of rapid POC germline DNA assays that could add 
value during the waiting period from sample collection to report generation. When used as a first-line 
screening assay during a genomic counselling session, BRCA1/2 and/or CYP2D6 pharmacogenetic 
testing may provide a cost-effective entry level for implementation of personalised medicine.  
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Figure 3: Pathology-supported genetic testing strategy incorporating multiple assay platforms to facilitate improved quality 
assurance on which to base treatment decisions.  
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Chapter 2 
Rationale & Aims 
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2.1.  Purpose 
The purpose of this study is to translate research into clinical practice using an integrated service and 
research approach. This involves the ongoing development and improvement of a central genomics 
database generated at the interface between the laboratory and clinical practice. Pathology assessments 
and results obtained with different assays performed on genetic material extracted from breast tumours 
and blood or saliva samples of the same patients, evolved into a pathology-supported genetic testing 
(PSGT) platform for comparative effectiveness studies. Follow-up studies are performed in 
collaboration with participating clinicians to identify patients who developed secondary cancer or 
relapsed. This may be due to genetic variation in genes underlying cancer susceptibility or drug 
resistance, and/or non-compliance to anti-cancer therapy due to medication side effects. The well-being 
of breast cancer patients relying on the MammaPrint test to determine the need for chemotherapy, and 
CYP2D6 genotyping for assessment of Tamoxifen resistance, was an important consideration in 
choosing point-of-care technology (POCT) as the method of choice for BRCA1/2 founder/recurrent 
mutation testing, following test development and analytical validation at the Laboratory of Government 
Chemist Limited (LGC) in the UK.    
2.2.  Study aim 
The primary aim of this study was to compare the frequency of BRCA1/2 founder/recurrent mutations 
between early-stage breast cancer patients with a MammaPrint low- versus high-risk profile. The 
secondary aim was to evaluate the clinical outcome (cancer recurrence) of breast cancer patients with a 
pathogenic BRCA1/2 variant in relation to CYP2D6*4 intermediate- or poor metabolizer status.  
2.3.  Rationale 
Currently, the application of PSGT to address different aspects of the same disease is limited to patients 
with private health care insurance. This problem is of particular relevance to the RNA-based 70-gene 
expression profile (MammaPrint®) with level 1A evidence for safe avoidance of chemotherapy in early-
stage breast cancer patients (Cardoso et al. 2016). Although this microarray test is one of the most 
expensive genomic assays available in South Africa, reimbursement as part of oncology benefits by 
most medical schemes is based on reduced chemotherapy expenditure and improved well-being of 
patients who are spared the side effects of treatment. Recurrence risk assessment using the 70 genes 
analysed to obtain the MammaPrint high/low score based on RNA extracted from formalin fixed 
paraffin embedded (FFPE) tumour tissue, is usually performed in conjunction with functional tumour 
subtyping including 80 genes (BluePrint®) on the same microarray. Combined use of these two 
microarray assays outperforms approximation of tumour molecular subtypes using standard 
immunohistochemistry (IHC) (Whitworth et al. 2017).   
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IHC assessment of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor-2 (HER2) status forms part of the MammaPrint/Blueprint microarray pre-screen 
algorithm (MPA) developed as a cost-saving strategy in South Africa (Grant et al. 2013, 2019; Myburgh 
et al. 2016, Pohl et al. 2016). The finding that “biology matters, and it is more than just expression of 
ER” (Groenendijk et al. 2019: 5), warrants further study to determine the appropriateness of adding 
germline DNA testing to microarray analysis of tumour DNA/RNA. The central genomics database 
developed during implementation of the MammaPrint test in South Africa provides a valuable resource 
for this purpose, beyond a single research objective (Figure 4).  
 
Figure 4: Introducing the MammaPrint test into the South African healthcare system by establishing a patient database at the 
interface between the laboratory and the clinic. A systematic approach was undertaken by using a pathology-supported genetic 
testing (PSGT) strategy to complement current testing procedures and establish clinical utility of gene profiling in early-stage 
breast cancer (Reproduced with permission from KA Grant PhD thesis, 2015)  
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The value of PSGT to bring together different test applications on the same platform was first 
demonstrated in a female breast cancer patient diagnosed with bilateral hormone receptor-positive 
breast cancer in 2008. She remains disease-free to date, despite omission of chemotherapy based on a 
low-risk MammaPrint profile for both tumours; which were classified by histopathology as invasive 
ductal/of no special type and lobular carcinomas (Grant et al. 2013). Additionally, Tamoxifen treatment 
was terminated in 2009 due to side effects unrelated to cytochrome P450 2D6 (CYP2D6) 
pharmacogenetics (van der Merwe et al. 2017).  Pathway-based whole exome sequencing (WES) using 
the PSGT framework (Figure 1) proved to be a valuable tool to help distinguish between inherited and 
lifestyle-related breast cancer, or a combination of both in this family. The daughter of the above-
mentioned patient with bilateral breast cancer was not referred for MammaPrint when aggressive 
HER2-positive breast carcinoma of no special type was diagnosed in 2010, as chemotherapy and anti-
HER2 treatment was clearly indicated in this patient with early-onset breast cancer (<30 years). Full 
gene BRCA1/2 DNA screening was negative in both the mother and daughter based on high-coverage 
germline NGS followed by WES. In 2018, the daughter developed liver metastasis, which was flagged 
on the PSGT platform when next generation sequencing (NGS) on tumour DNA was requested by her 
oncologist for identification of a gene-targeted therapy. When the NGS results of 75 cancer-related 
genes using the method described by Laes et al. (2018) became available, these were compared to the 
WES data obtained from her germline DNA three years earlier. This helped to identify a sequencing 
error in her tumour DNA and prevention of inappropriate treatment. This patient is currently in 
remission as IHC-based gene expression data, also provided in the NGS report, led to effective treatment 
of the liver metastasis.  
Clinical monitoring over more than a decade in the above-mentioned family confirmed the value of a 
sustainable cancer genomics database with patient information collected at the protein, RNA and DNA 
levels in different laboratories. Tumour heterogeneity explained by these findings and germline WES 
results were important considerations in the selection of negative and positive controls used in this study 
to evaluate the clinical relevance of BRCA1/2 founder/recurrent mutation testing using POCT. The 
sequential informed consent process and ethics approval obtained for this process furthermore 
contributed to the development of a framework for tiered informed consent for genomic health research 
applicable to Africa (Nembaware et al. 2019). 
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3.1.  Ethics approval 
Ethics approval was obtained from the Health and Wellness Sciences Research Ethics Committee 
(CPUT/HW-REC 2018/H10) of the Cape Peninsula University of Technology. This project was also 
registered as a sub-study under reference number N09/06/166 by the Health and Research Ethics 
Review Committee (HREC) of Stellenbosch University.  
3.2.  Study design  
A pathology-supported genetic testing (PSGT) platform established at the interface between the 
research laboratory and routine clinical practice was used to develop a genomics database (Kotze at el, 
2015), which was mined in this study to extract information of eligible breast cancer patients (Figure 
4). All study participants were previously referred for the 70-gene MammaPrint test (2008-2019), 
followed by CYP2D6*4 genotyping performed between 2012 and 2019. BRCA1/2 mutation status was 
determined using a point-of-care (POC) assay that can be performed within 1-2 hours. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Database of breast cancer patients referred for both the MammaPrint 
test (>500) and CYP2D6*4 genotyping (>1000) 
 
Tumour genetics           
Low Recurrent Risk  
 
Tumour genetics        
High Recurrence Risk  
 
BRCA1/2 founder/recurrent mutation detection using a rapid POC assay  
 
Determine the appropriateness of incorporating BRCA1/2 mutation status and CYP2D6 
pharmacogenomics into the MammaPrint pre-screen algorithm for recurrence risk 
assessment 
• Therapy-associated risk assessment based on tumour genetics and germline 
pharmacogenomics  
• Familial risk assessment in relation to BRCA1/2 mutation status and referral 
for genetic counselling, if not already performed 
 
Germline genetics 
CYP2D6*4 genotyped  
Informed 
consent 
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Figure 5:  Flow chart illustrating the research plan using a pathology-supported genetic testing platform (PSGT) for data 
extraction and extended analysis of available DNA samples using a newly-developed point-of-care (POC) assay including 
eight pathogenic BRCA1/2 variants previously identified at an increased frequency in the South African population due to a 
founder/recurrent effect. 
3.3.  Data collection 
This study was performed in South African patients with breast cancer previously subjected to tumour 
genomic risk profiling using the 70-gene microarray (MammaPrint®) test as previously described by 
Grant et al. (2013). Routine histopathology and immunohistochemistry (IHC) reports including 
assessment of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor-2 (HER2) status were reviewed and entered into the genomics database. From 2010, the 80-
gene microarray (BluePrint®) was added to the MammaPrint service alongside ER, PR, and HER2 
approximation of intrinsic molecular subtypes (Grant et al. 2015, 2019). From 2012, results from 
pharmacogenetics CYP2D6 genotyping was added to the PSGT platform after obtaining informed 
consent for inclusion of information in the genomics database (van der Merwe et al. 2012a, 
2017).Patients are recruited on an ongoing basis by treating clinicians and their information is available 
in the genomics database freely available to registered users at www.gknowmix.org (Kotze et al. 2013). 
New data are added to the PSGT platform as results of histopathology and laboratory tests become 
available during routine clinical practice (Kotze 2016).  Written informed consent was obtained from 
all patients who provided blood or saliva for germline genetic testing.  
Breast cancer patients with a low-risk MammaPrint profile were administered only endocrine therapy 
by their treating clinicians, without the addition of chemotherapy. Patient referrals from 2007 were 
closely monitored while awaiting the outcome of the prospective Microarray in Node Negative and 1 
to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) trial, which demonstrated 
the highest level 1A evidence of clinical utility (Cardoso et al. 2016). Use of the PSGT platform for 
identification of patients with recurrent or a second primary cancer was an important consideration as 
mutation detection in tumour or germline DNA during follow-up may alter their treatment (Grant et al. 
2013).  
3.3.1. Inclusion criteria 
• Samples from individuals diagnosed with breast cancer and subjected to tumour genomic 
testing, who subsequently relapsed or developed secondary tumours 
• Samples from participants where other molecular cancer genetic testing results are available 
for comparison, including high-penetrance BRCA1/2 mutations and/or polymorphisms in the 
CYP2D6 gene, screened for in DNA extracted from the tumour, blood and/or saliva samples 
• Samples with available genetic test results in the database approved for research under the 
parent gene profiling project (Number N09/06/166)  
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3.3.2. Exclusion criteria 
• Use of samples from breast cancer patients who are non-consenting to germline genetic analysis  
3.4.  Pathology-supported genetic testing 
ER, PR and HER2 status assessed by IHC were obtained from accredited pathology laboratories at 
referral of breast cancer patients for MammaPrint microarray testing performed at Agendia in the 
Netherlands. Hormonal status for ER and PR was based on the proportion of positive staining cells and 
staining intensity, while HER2 status was determined by IHC and/or fluorescence in situ hybridisation 
(FISH) in equivocal cases (2+). These results obtained at the protein level for approximation of the four 
major tumour subtypes, luminal A, luminal B, HER2-enriched and basal-type, were incorporated into 
the MammaPrint pre-screen algorithm (MPA) developed and implemented as a cost-saving strategy in 
South Africa (Grant et al. 2013; Myburgh et al. 2016). In this study, eight germline BRCA1/2 
founder/recurrent mutation status was assessed in early-stage breast cancer patients in relation to tumour 
subtype and CYP2D6 pharmacogenetics in order to determine the appropriateness of including 
clinically relevant germline variants in these genes in the MPA for test selection and/or improved 
clinical interpretation/management. This was deemed necessary due to detection of both a pathogenic 
BRCA2 c.7934delG founder/recurrent variant and the CYP2D6*4 pharmacogenetics biomarker in 
tumour DNA of a South African female patient (index case) diagnosed with bladder cancer four years 
after referral for the MammaPrint test. Testing of two different tests in the same patient a few years 
apart was flagged on the PSGT platform, following next generation sequencing (NGS) of the patients’ 
tumour DNA performed in conjunction with IHC (OncoDNA, Belgium). A database query resulted in 
53 samples, of which 50 with both MammaPrint (tumour) and CYP2D6 (germline) results were selected 
for extended BRCA1/2 founder/recurrent mutation screening in this study. Two samples were excluded 
based on informed consent requirements. The third sample had a pathogenic CHEK2 variant 
(rs555607708) previously detected by whole exome sequencing (WES) and was used as one of the 
negative controls for the eight BRCA1/2 founder/recurrent mutations analysed in this study. Clinical 
outcome of patients with results obtained using the BRCA POC test were compared with data 
previously documented in the genomics database, including BRCA1/2 results available for a small 
number of patients. Patients without follow-up data already captured in the genomics database were 
contacted, where possible, in collaboration with their treating oncologists to obtain current information 
for inclusion in the research database based on the informed consent provided. 
3.5.  DNA extraction 
DNA was available for all 50 cancer patients and 10 control samples included in this study. For DNA 
extraction from whole blood the QIAamp DNA Mini Kit was used. Twenty microliters (20 μl) of 
protease was pipetted into a 1.5 ml microcentrifuge tube. Two hundred microliters of venous blood was 
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added to microcentrifuge tube, followed by 200 μl of AL Buffer and vortexed for 15sec. After 
incubation at 56°C for 10 min 200 μl of 100% ethanol was added to the sample and mixed by vortexing 
for 15 sec. The mixture was applied to a QIAamp Mini spin column and centrifuged at 8000 rpm for 1 
min. The mini-spin column was placed in a clean 2 ml collection tube and the filtrate was discarded.  
Wash buffer (500 μl) was added into the mini-column and centrifuged at 8000 rpm for 1 min. The mini-
spin column was placed in a clean 2 ml collection tube and the filtrate was discarded.  Five hundred 
microliters (500 μl) of AW2 buffer was added to the mini-column, then centrifuged at 14000 rpm for 3 
min. The mini-spin column was placed in a new 2 ml collection tube and centrifuged at full speed for 1 
min. After centrifuging the mini-column, 200 μl of Buffer AE was added and incubated at room 
temperature 15oC - 25oC for 1 min and centrifuged at 8000 rpm for 1 minute. The quality and 
concentration of the extracted DNA were assessed with a Nanodrop One spectrophotometer (Nanodrop 
Technologies, Wilmington, USA) before analysis. Samples analysed using Nanodrop had an optical 
density ratio A260/A280 >1.8. 
3.6.   BRCA1/2 point-of-care  genetic testing 
PCR amplification and melting curve analysis of eight BRCA1/2 founder/recurrent mutations previously 
identified in the South African population (Reeves et al. 2004; van der Merwe and van Rensburg 2009; 
van der Merwe et al. 2012b) were performed using the BRCA 1.0 POC Research Kit and 
instrumentation (Laboratory of Government Chemist Limited, LGC, Teddington, UK).  Kit 
development by LGC was based on the ParaDNA POC genotyping principles as previously described 
(Pirmohamed et al. 2013).  The reaction plate kits (BRCA 1.0) were stored at -20oC and thawed at room 
temperature for 15-20 min before use. DNA samples were diluted to a concentration of 1 ng/ul, and 2 
ul of each sample transferred into each well of the ParaDNA reaction plates. Prior to the analysis of 50 
DNA samples available for this study, 1 blank, 2 negative controls, and eight positive control samples 
of known genotype for each founder/recurrent mutation were tested. The ParaDNA kits comprised all 
the reagents required for multiplex melt curve analysis of the eight BRCA1/2 targets in a four-tube 
format (Table 6) using the fluorescent dyes FAM, CAL Fluor Orange 560 (CAL560) and CAL Fluor 
Red 610 (CAL610). Following an initial denaturation step (98°C for 1 min), the targets were amplified 
using 50 PCR cycles of 99°C for 7 sec, 62°C for 12 sec and 72°C for 12 sec, followed by denaturation 
at 95°C for 20 sec and probe annealing at 35°C for 30 sec. After PCR amplification, the reactions were 
denatured (95°C for 20 sec) and cooled (35°C for 30 sec). Melting curve analysis was performed by 
heating the samples from 35°C to 80°C using a 0.1°C/s ramp rate and fluorescence acquisition. The 
ParaDNA software (version 1.6.0.27) automatically analysed the sample melting curves and reported 
the BRCA1/2 genotypes on the computer screen. Automated software calls were assessed using the 
ParaDNA Data Review software to examine sample melting curves. 
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Table 5: Multiplex analysis of eight BRCA1/2 founder/recurrent mutations in a four-tube ParaDNA format.  
Tube Gene Founder/recurrent 
mutation 
Variant Probe label 
A BRCA1 c.1374delC rs397508862 FAM 
BRCA2 c.7934delG rs80359688 CAL560 
B BRCA1 c.2641G>T rs39750888 FAM 
BRCA2 c.5771_5774delTTCA rs80359535 CAL560 
C BRCA1 c.5266dupC rs80357906 FAM 
BRCA1 c.68_69delAG rs80357914 CAL610 
D BRCA2 c.6448_6449insTA rs397507858 FAM 
BRCA2 c.5946delT rs80359550 CAL560 
3.7.  Sanger sequencing 
Sanger sequencing was used as the gold standard for confirmation of the genotypes of the control 
samples and to confirm the results obtained with the BRCA 1.0 POC Research assay. The standard 
operating procedure (SOP) developed at the Pathology Research Facility was followed before 
submission of samples for Sanger sequencing at the Central Analytical Facility, Stellenbosch 
University. Table 7 shows the oligonucleotide primers used for Sanger sequencing as obtained from the 
SOP. Electropherograms were analysed using the Ensembl human reference sequence for direct 
comparison. 
Table 6: Oligonucleotide primers used for conventional polymerase chain reaction application and Sanger sequencing of 
BRCA1 (NM_007300.4) and BRCA2 (NM_000059.3). 
Gene 
 
Regio
n 
Variant Primer Oligonucleotide primers (5’ to 3’) Size 
(bp) 
BRCA
1 
 
 
Exon2 c.68_69delAG 
 
F TGTGTTAAAGTTCATTGGAACA  
149 R CATAGGAATCCCAAATTAATACA 
Exon 
11 
c.1374delC 
 
F TCGCATGCTCAGAGAATCC  
400 R TGTGGCTCAGTAACAAATGCTC 
Exon 
11 
c.2641G>T 
 
F GCTCAGTATTTGCAGAATAC  
253 R GCTTATCTTTCTGACCAACC 
Exon 
20 
c.5266dupC 
 
F AGTCAGAGGAGATGTGGTCAATGG  
236 R GTGGTTGGGATGGAAGAGTGAA 
BRCA
2 
 
 
Exon 
11 
c.5946delT 
 
F CGAGGCATTGGATGATTCAGAG  
394 R GAGCTGGTCTGAATGTTCGTTAC 
c.6448_6449insTA 
 
F GAGAAACCCAGAGCACTGTG  
404 R CTAAGATAAGGGGCTCTCCTC 
c.5771_5774delTTCA F CGAGGCATTGGATGATTCAGAG 
394 R GAGCTGGTCTGAATGTTCGTTAC 
Exon 
17 
c.7934delG 
 
F GTAGTTGTTGAATTCAGTATC  
354 R TGGCAACTGTCACTGACAAC 
 
 
The reagents and PCR conditions used for sanger sequencing is shown in table 8 and 9 respectively.  
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Table 7: Master mix preparation for  c.7934delG 
Reagents 
Nuclease Free Water 15.675 
5x buffer 5 
MgCl2 (25mM) 1.5 
dNTP mix (10mM) 0.5 
Forward Primer (10 μM) 0.6 
Reverse Primer (10 μM) 0.6 
Go Taq Polymerase 0.125 
DNA template (10ng/ μl) 1 
Total 25 
 
 
Table 8: Thermal cycling condition for c.7934delG 
Steps Cycles Temperature (0C) Time(min) 
Initial denaturation 1 95 02:00 
Denaturation 30 95 00:30 
Annealing 30 62 00:30 
Final extension 30 72 05:00 
 
3.8. Statistical analysis 
Qualitative characteristics were described using cross tabulation and frequency tables analysed using 
the STATISTICA package. One-way ANOVA was used to compare average age between subgroups. 
The significance level was set at 0.05 for determination of statistical significance. 
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4.1.  Characteristics of the study population  
Table 10 shows the clinical characteristics of the study population, subdivided into 26 breast cancer 
patients with a low-risk MammaPrint profile (52%) and 24 with a high-risk profile (48%). Four (8%) 
of these patients also had bilateral or other forms of cancer, including the index case (MPR 055) 
diagnosed with bladder cancer four years after referral for the MammaPrint test. Two low-risk patients 
that are non-mutations carriers developed basal cell cancer and colon cancer respectively. One patient 
with a high-risk profile and a non-mutation carrier developed breast cancer on the opposite breast (left). 
The average age of the study cohort of predominantly Afrikaners of European ancestry, was 51 (34-74) 
years, with no substantial difference between the mean age of patients with low- and high-risk tumours. 
Notably, 6 (24%) premenopausal patients below the age of 40 years have a high risk for distant 
recurrence, while only one patient (4%) in this age group had a low-risk genomic risk profile. Most of 
the patients included in this study were diagnosed with ductal/carcinoma of no special type (82%), with 
a similar distribution of high- and low-risk MammaPrint profile.  Of the six lobular cancers, four were 
reported as low risk and two as high risk. Only one patient had an ER-negative tumour, which was 
categorised as high-risk for recurrence. In the high and low-risk groups an equal number of patients had 
PR-negative tumours.  Of the 50 patients included in the study, 16 of their tumours (38%) were scored 
by immunohistochemistry (IHC) as equivocal HER2 (2+) and referred for fluorescence in situ 
hybridization (FISH) analysis. Using FISH, 12 (75%) of the 16 tumours which were found to be 2+/3+ 
on IHC, were reported as HER2 negative, one remained equivocal and three (18.8%) demonstrated 
HER2 amplification (Table 11). Sixty percent (30/50) of the patients reported a family history of cancer 
(data not shown). After stratification based on genomic recurrence risk, a similar family history of 
cancer was seen in high and low-risk groups.  
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Table 9: Clinical characteristics of the study population of predominantly European ancestry stratified by MammaPrint 
recurrence risk profile. 
IHC, immunohistochemistry; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth 
factor receptor-2  
 
Table 10: Fluorescence in situ hybridization (FISH) verification of 16 tumours assessed by immunohistochemistry (IHC) as 
equivocal (2+) or positive (3+). 
   FISH 
  n=16 Negative Positive Equivocal 
IHC 2+ 11 (68.8%) 10 (62.5%) - 1(6.2%) 
3+ 5 (31.2%) 2 (12.5%) 3 (18.8%) - 
TOTAL   12 (75%) 3 (18.8%) 1 (6.2%) 
 
4.2.  BRCA1/2 genotyping using the ParaDNA POC Assay 
Before testing the DNA samples of patients included in this study, the performance of the BRCA 1.0 
Research Kits was verified using 10 DNA samples of known genotype for each of the eight BRCA1/2 
founder/recurrent variants as controls, as well as a blank containing no DNA (Figure 5). All samples 
were genotyped using a 3-colour, 4-tube multiplex assays, after adding the extracted DNA to each of 
Characteristics All patients (n=50) Low risk (n=26)  High risk (n=24)  
Age mean (years) 50.68 years (36-74)  51.54 years (36-74) 49.75 years (34-73) 
<40 
41-50 
>51 
7 (14%) 
19 (3%) 
24 (48%) 
1 (4%) 
12 (46%) 
13 (50%) 
6 (25%) 
7 (29%) 
11 (45%) 
IHC ER status 
Positive 
Negative 
 
49 (98%) 
1 (2%) 
 
26 (100%) 
0 
 
23 (96%) 
1 (4%) 
IHC PR status 
Positive 
Negative 
 
46 (92%) 
4 (6%) 
 
25 (96%) 
1 (4%) 
 
21 (88%) 
3 (12%) 
IHC HER2 status 
1+ 
2+ 
3+ 
Not provided 
 
7 (14%) 
11 (22%) 
5 (10%) 
27 (54%) 
 
3 (12%) 
8 (30%) 
1 (4%) 
14 (53%) 
 
4 (17%) 
3 (12%) 
4 (17%) 
13 (54%) 
Tumour Type 
Lobular 
Ductal 
Not provided 
 
6 (12%) 
41 (82%) 
3 (6%) 
 
4 (15%) 
21 (80%) 
1 (4%) 
 
2 (8%) 
20 (83%) 
2 (8%) 
Grade 
1 
2 
3 
Not provided 
 
16 (32%) 
23 (46%) 
2 (4%) 
9 (18%) 
 
9 (35%) 
11 (42%) 
0 
6 (23%) 
 
7 (29%) 
12 (50%) 
2 (8%) 
3 (12%) 
Family history of cancer 
Yes 
No 
Not provided 
 
30 (60%) 
7 (14%) 
13 (26%) 
 
15 (58%) 
4 (15%) 
7 (27%) 
 
15 (62%) 
3 (12%) 
6 (25 %) 
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the four plate wells. The test duration from sample-to-result was 60 minutes. The ParaDNA software 
automatically analysed the multiplex melting curve data and assigned sample genotype calls. The 
accuracy of software calls was assessed by adding different DNA samples, comprising known South 
African founder/recurrent mutations, to each well of ParaDNA plates. All of the samples and negative 
controls were assigned the correct software calls using 2 ng of input DNA.  
 
 
 
Figure 6: BRCA1/2 genotyping of control samples using the BRCA 1.0 POC Kit. Melting curve analysis of founder/recurrent 
mutations BRCA1 c.68_69delAG, c.1374delC, c.2641G>T, c.5266dupC and BRCA2 c.5771_5774delTTCA, c.5946delT, 
c.6448_6449insTA, c.7934delG (A-H).  By using FAM-labelled HyBeacon (green), melting peaks were correctly detected for 
pathogenic variants BRCA1 c.1374delC (rs397508862) (A), BRCA2 c.6448_6449insTA (rs397507858) (B), BRCA1 
c.2641G>T (rs397508988) (C), BRCA1 c.5266dupC (rs80357906) (D), while CAL 560 probes (orange) detected BRCA2 
c.5771_5774delTTCA (rs80359535) (E), BRCA2 c.5946delT (rs80359550) (F), BRCA2 c.7934delG (rs80359688) (G) and the 
CAL 610 probe identified the pathogenic variant BRCA1 c.68_69delAG (rs80357914) (H) using controls with known BRCA1/2 
mutations. No peaks are shown in (I), corresponding to the blank sample with no DNA, while the two negative controls each 
generated one peak, corresponding to the samples without any of these pathogenic variants (J and K). 
After the accuracy of the method used for BRCA1/2 founder/recurrent mutation detection was 
confirmed, germline DNA of 50 breast cancer patients previously analysed using the 70-gene 
MammaPrint were genotyped. Five of the patients tested positive for the pathogenic BRCA2 c.7934delG 
variant. For one of the samples with a low risk MammPrint profile, four of the eight founder/recurrent 
mutations tested failed despite repeat analysis (two times), due to poor quality of the stored DNA used. 
Homozygous wild-type (wt) samples generated single melting peaks, whereas heterozygous samples 
A B C 
D E F 
G H I 
J K 
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with pathogenic variants generated two peaks (wt & mut).  All five samples (Peak 1) with the pathogenic 
BRCA2 c.7934delG variant generated melting peaks at 50 0C (Figure 7), as confirmed by Sanger 
sequencing (Figure 8). The FAM rs397508862, FAM rs397508988, CAL560 rs80359535, FAM rs3 
80357906, CAL610 rs80357914, FAM rs397507858 and CAL560 rs80359550 HyBeacon probes 
generated 44 single wt melting peaks indicating that none of the other BRCA1/2 founder/recurrent 
mutations (Peak 2) tested for were present in the DNA samples successfully tested. The lower peaks 
were either due to poor sampling quality, low DNA concentration or mass loss from improper plate 
sealing. 
 
 
Figure 7: BRCA1/2 genotyping of breast cancer patient samples using the BRCA 1.0 POC Kit Melting curve analysis of eight 
BRCA1/2 founder/recurrent mutations BRCA1 c.68_69delAG, c.1374delC, c.2641G>T, c.5266dupC and BRCA2 
c.5771_5774delTTCA, c.5946delT, c.6448_6449insTA, c.7934delG (A-H). CAL 560 probe detected five of the patients tested 
positive for the pathogenic BRCA2 c.7934delG variant (Peak 1). No pathogenic variants were detected in 44 DNA samples 
(Peak 2). 
4.3.  Confirmation by Sanger sequencing 
Detection of BRCA2 c.7934delG using the BRCA 1.0 POC Kit was confirmed by Sanger sequencing, 
as shown for the index case in Figure 8. This founder/recurrent mutation was initially detected in DNA 
extracted from the bladder tumour. 
1 
2 
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Figure 8: Confirmation of BRCA2 c.7934delG detected by the BRCA 1.0 POC Kit using Sanger Sequencing.  
4.4.  BRCA2 c.7934delG, age of onset and MammaPrint risk profile 
As shown in Figure 9, patients with the BRCA2 c.7934delG founder/recurrent mutation were diagnosed 
with breast cancer at a significantly younger age than those without this pathogenic variant (p=0.02).  
Clinical features of 49 patients successfully genotyped for all eight BRCA1/2 founder/recurrent 
mutations are compared in Table 12. 
 
Figure 9: Comparison of the mean age between the five breast cancer patients identified with the BRCA2 c.7934delG 
founder/recurrent mutation versus the 44 non-mutation carriers. 
 
Three of the 24 patients with a high-risk MammaPrint profile (12%) and two of the 26 low-risk cases 
(8%) tested positive for the BRCA2 c.7934delG mutation. Use of the validated Manchester score 
including histopathology criteria to estimate the likelihood of harbouring a pathogenic BRCA1/2 
BRCA2_code; LS Means
Current effect: F(1, 47)=5.4876, p=0.02 
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
negative positive
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variant, showed that only one patient with a high-risk MammaPrint profile would have qualified for 
BRCA1/2 testing, with a score of 29.  
 
Table 11: Comparison of clinical features between breast cancer patients with and without the BRCA2 c.7934delG 
founder/recurrent mutation, grouped according to their MammaPrint recurrence risk profile.  
BRCA1/2 Result Negative (n= 44) Positive (n=5) 
70-gene Result Low (n=23)  High (n=21) Low (n=2) High (n= 3) 
Age, average 
(range) 
52 years (36-74) 51years (34-73) 42.5years (36-47) 
 
41 years (34-47) 
Family history 
Yes 
No 
Not provided 
 
 
14 (61%) 
2 (9%) 
7 (30%) 
 
12 (57%) 
3 (14%) 
6 (29%) 
 
0 
2  
 
3  
0 
Tumour Type 
Ductal 
Lobular 
Not provided 
 
19 (83%) 
4 (17%) 
0 
 
17 (81%) 
2 (9.5%) 
2 (9.5%) 
 
2 
0 
0 
 
3 
0 
0 
ER status 
Positive 
Negative 
 
23 (100%) 
 
20 (95%) 
1 (5%) 
 
2 
0 
 
3 
0 
PR status 
Positive 
Negative 
 
22 (96%) 
1 (4%) 
 
18 (86%) 
3(14%) 
 
2 
0 
 
3 
0 
HER2 status 
1+ 
2+ 
3+ 
Not provided 
 
1 (4%) 
7 (30%) 
1 (4%) 
14 (61%) 
 
3 (14%) 
3 (14%) 
2 (9.5%) 
13 (62%) 
 
2 
0 
0 
0 
 
1 
0 
2* 
0 
Ductal Ca Grade 
1 
2 
3 
Not provided 
 
9 (39%) 
9 (39%) 
0 
5 (22%) 
 
7(33%) 
10 (48%) 
1 (5%) 
3 (14%) 
 
0 
2  
0 
0  
 
0 
2 
1 
0 
*Microarray analysis reported HER2-negative status, subsequently confirmed using reflex FISH (Grant et al. 
2015). Case 291 with a low-risk MammPrint profile was excluded due to failure to detect four of the eight 
BRCA1/2 variants tested for. 
 
 
4.5.  BRCA2 c.7934delG and CYP2D6 pharmacogenetics  
CYP2D6*4 genotyping previously performed in the study population detected one homozygote with 
the poor metabolizer status (2%) and 18 heterozygotes with the intermediate metabolizer status (36%).   
Of the five patients with the pathogenic BRCA2 c.7934delG variant, three were heterozygous for 
CYP2D6*4, including the index case and two patients with a high-risk MammaPrint profile. Follow-up 
studies revealed that only the index case previously shown to have a low-risk MammaPrint profile is 
deceased. The two patients with a high-risk MammaPrint profile found to be heterozygous for 
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CYP2D6*4 received this pharmacogenetic information relevant to the selection of Tamoxifen earlier in 
their cancer treatment process compared to the index case selected for this study after referral for NGS 
on tumour DNA.  
The index case was diagnosed with ductal carcinoma in situ at the age of 47 years, and invasive ductal 
carcinoma of no special type (grade 1, ER/PR 3+, HER2 negative) at the age of 51 years, resulting in 
the initial referral for the MammaPrint test which showed a low-risk profile for breast cancer recurrence. 
Four years later, this patient, initially treated with Tamoxifen, was diagnosed with invasive urothelial 
(transitional) cell carcinoma grade III. BRCA2 c.7934delG identified in the bladder tumour was 
confirmed in the patient’s germline DNA (Figure 8), which also showed genetic variation in the 
CYP2D6 drug metabolism pathway. The existence of two malignancies having different histopathology 
and at anatomically distinct sites, suggested the diagnosis of metachronous malignancy involving the 
breast and the bladder. IHC testing performed on the bladder biopsy tissue showed cytokeratin 20 and 
7, p63, 34Be12 and p504s positive staining. Morphological characteristics of the bladder tumour was 
not consistent with that of an infiltrating ductal carcinoma of no special type, previously diagnosed in 
the breast biopsy. This confirmed a primary bladder cancer and ruled out breast cancer metastasis due 
to misclassification with use of the MammaPrint test.  
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The database query performed in this study was resticted to breast cancer patients referred for the 70-
gene MammaPrint test using RNA extracted from tumour biopsies as part of routine clinical care, as 
well as germline CYP2D6 genotyping following written informed consent for additional germline 
genetic testing. CYP2D6*4 was initially detected in the presence of BRCA2 c.7934delG in tumour DNA 
of a tamoxifen-treated patient with metachronous malignancies involving the breast and the bladder. 
These findings prompted confirmation of the BRCA2 c.7934delG founder/recurrent mutation in 
germline DNA of this “index case” in 2018. This finding supported subsequent development of a rapid 
point-of-care (POC) BRCA assay used in this study to screen 50 breast cancer patients for eight 
relatively common BRCA1/2 founder/recurrent mutations previously described in the South African 
population (Reeves et al. 2004; van der Merwe and van Rensburg 2009; van der Merwe et al. 2012b). 
Verification of the BRCA1/2 results obtained for the eight founder/recurrent mutations tested was 
obtained blindly by DNA sequencing or comparison with previous patient reports provided by 
participating clinicians.  Reports of previous BRCA/other gene panel testing was available for 
comparison in five patients with the BRCA2 c.7934delG variant and eight patients without BRCA2 
variants based on founder/recurrent mutation testing or extended gene panels.  
5.1.  MammaPrint risk profile distribution in relation to BRCA2 c.7934delG  
BRCA2 c.7934delG was the only pathogenic variant detected in five of the study participants, with a 
slightly higher proportion of affected cases classified with a high recurrence risk based on the 
MammaPrint test. The age at diagnosis did not differ between South African breast cancer patients with 
a high- and low-risk MammaPrint profile, while patients with the BRCA2 c.7934delG founder/recurrent 
mutation developed breast cancer at a significantly earlier age than non-carriers. It therefore seems 
unlikely that a large number of pathogenic variants other than BRCA2 c.7934delG were missed in the 
study cohort due to use of the BRCA 1.0 Research POC assay limited to eight founder/recurrent 
mutations.  
The MammaPrint risk score distribution in South African breast cancer patients with the BRCA2 
founder/recurrent mutation showed a similar pattern compared to that previously reported in oestrogen 
receptor (ER) positive BRCA1/2 carriers screened with the 21-gene assay (OncotypeDX) assay (Lewin 
et al. 2016; Halpern  et al. 2017). In the study performed by Lewin et al. (2016) assessing germline 
BRCA1/2 mutation status in Israel, the 21-gene recurrence score distribution shifted towards high 
(BRCA1 50 % and BRCA2 29%) and intermediate (BRCA1 35% and BRCA2 52%) risk compared to a 
small proportion in low-risk cases (BRCA1 15 % and BRCA2 18.4%). It remains uncertain whether ER-
positive early-stage breast cancer patients with pathogenic BRCA1/2 germline variants could safely 
avoid chemotherapy based on tumour gene profiling, as gene targeted therapies such as PARP  
inhibitors may be more appropriate.  Age is also an important consideration with use of the OncotypeDX 
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test as the TailorX trial showed that premenopausal women 50 years of age or younger at the higher 
extreme of the intermediate-risk range (16-25) may have a small benefit from chemotherapy (Sparano 
et al. 2018).  
Detection of the same South African founder/recurrent mutation in breast cancer patients selected for 
microarray testing by clinico-pathological features incorporated in the MammaPrint pre-screen 
algorithm (MPA) using pathology-supported genetic testing (PSGT), has the advantage that a search 
for other risk modifiers in the causal pathway involving BRCA2 c.7934delG can be further explored. 
Apart from Giusti et al. (2003) who found no differentiating clinical or pathological characteristics 
among prostate cancer patients with the same Ashkenazi Jewish founder mutation, when compared to 
non-carriers, this study is the first investigation of South African cancer patients selected by tumour 
subtype with the same founder/recurrent mutation. Detection of germline pathogenic BRCA1 variants 
in patients with hormone-receptor positive cancer were initially disregarded as incidental or sporadic, 
but a more plausible explanation may be that age-related metabolic changes combined with 
environmental exposures predisposing to genomic instability may produce different tumour subtypes 
within the same genetic background (Tung et al. 2010). Indeed, Naushad et al. (2012) demonstrated that 
dysfunction of one-carbon metabolism as reflected by raised homocysteinaemia may predict breast 
cancer subtype and disease progression.  Other subtype-specific factors include body mass index (BMI), 
age of cancer onset and vitamin D status being explored in South African breast cancer patients with 
hormone receptor-positive breast cancer (Baatjes et al. 2019; Okunola et al. 2019).  These findings 
raised the question whether preventive strategies in cancer patients with the same pathogenic germline 
BRCA1/2 variant will change tumour pathology and hence have a positive impact on clinical 
management, in a similar way that cholesterol levels and other biochemical blood tests are used in 
cardiovascular disease (CVD) risk management. RNA-based gene profiling assays such as MammaPrint 
have not previously been studied in relation to BRCA1/2 mutation status using the PSGT platform to 
help overcome limitations of pathology and genetic tests when used in isolation.  
5.2. Tumour pathology of patients with pathogenic germline BRCA1/2 variants 
The breast cancer patients included in this study were categorized by age, hormonal status, tumour type 
and grade and underwent RNA-based tumour gene expression profiling using the 70-gene microarray-
based assay. On histopathology, BRCA2 associated breast cancer is commonly categorised as luminal 
with few immunohistochemical (IHC) and morphological characteristics to distinguish it from sporadic 
disease. These cancers are generally hormone receptor-positive (ERα and PR), with low or negative 
HER2 expression (van der Groep et al. 2011). Numerous studies have reported a comparable incidence 
of ER/ PR-positive cancers in BRCA2 carriers associated with sporadic cases (Armes et al. 1999; 
Lakhani et al. 2002; Palacios et al. 2005). In a large series of BRCA2-associated breast cancer, Bane et 
al. (2007) showed a luminal subtype despite a predominantly high-grade phenotype of invasive ductal 
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carcinomas of no special type. These tumours were also less likely than control tumours to overexpress 
HER2/neu or the basal cytokeratin CK5, with no difference in expression of cyclin D1, MIB1, p53 and 
bcl2. 
In South Africa to improve cost-effectiveness, IHC ER/PR-positive and HER2-negative tumours are 
usually selected for genomic profiling using the MammaPrint and BluePrint assays, and therefore our 
cohort consisted predominantly of hormone receptor-positive tumours. As expected, most South 
African patients with a low recurrence risk had ER/PR-positive cancers, with one ER-negative case 
showing a high-risk MammaPrint profile. In some patients with HER2-positive tumours referred for 
the MammaPrint test, some were previously reclassified as negative using microarray analysis and vice 
versa (Grant et al. 2015).  The differences in tumour characteristics were not associated with a 
distinctive pattern in all five South African breast cancer patients with the BRCA2 c.7934delG variant, 
including one patient with IHC HER2 status reclassified by microarray analysis. 
There is a notable difference in the distribution of tumour grade in ER-negative and ER-positive breast 
cancer in BRCA1 carriers (Tung et al. 2010). One feature is that moderately or poorly differentiated 
tumours are more often reported in ER-positive BRCA2 breast cancer carriers than in patients with 
sporadic disease. This was evident in our study where 80% of the patients with the founder/recurrent 
BRCA2 c.7934delG variant versus 45% of the non-carriers, were diagnosed with grade 2/3 tumours. 
None of the breast cancer patients with the pathogenic BRCA2 variant had well differentiated tumours 
(grade 1), however, despite 36% (16/44) of non-mutation carriers diagnosed with grade 1 cancers, seven 
of these patients were reported as having a genomic high risk for recurrence. Only one patient with 
sporadic breast cancer had a poorly differentiated tumour and was regarded as high-risk according to 
MammaPrint. Tumour type associated with BRCA2 breast cancer is mostly infiltrating ductal 
carcinomas (van der Group et al. 2011), which was confirmed in our study.  
In a study of 217 women recruited from various clinical sites, Beumer et al. (2016) validated the 
prognostic value of the MammaPrint test in patients with early-stage invasive lobular carcinoma. An 
association was found between the MammaPrint high risk profile and an unfavourable clinical outcome 
in distant metastasis-free and overall survival. True HER2-amplified breast cancer is rare in BRCA1 
and even less frequent in BRCA2 mutation positive patients (Evans et al. 2016). However, this may be 
an underestimation due to enforcement of standard clinical guidelines for IHC staining used to 
determine the need for expensive anti-HER2 therapy. Current consensus is that only tumours reported 
as IHC 2+ are referred for FISH testing to determine the HER2 status when uncertain. In our previous 
study where IHC initially reported HER2 as negative while microarray analysis and reflex FISH testing 
revealed HER2 amplification (Grant et al. 2015), validity is supported by others who reported FISH 
amplification in 6% (Gown et al. 2008) and in up to 14% (Martin et al. 2012) of IHC 0/1+ samples. 
These discrepancies are not only due to pre-analytical factors or subjective interpretation of results, but 
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could be due to aberrant HER2 protein expression due to pathogenic germline variants not identified 
with routine immunostaining procedures. When comparing breast cancer patients in our study, BRCA2 
carriers with HER2-amplified cancers had predominantly high risk tumours based on MammaPrint 
scoring. Gene expression assessments propose that BRCA1/2 related cancers and HER2-positive cancer 
are two different entities, therefore assessment of other tumour markers may be more significant than 
HER2 to help predict the risk of an actionable BRCA1/2 variant in a patient to justify the cost of genetic 
testing (Maynes et al. 2010). The enrichment of the BRCA2 c.7934delG variant among South African 
breast cancer patients referred for MammaPrint warrants further study in an extended sample to 
determine whether the MPA can be used to select breast cancer patients for BRCA1/2 testing at the POC 
to facilitate clinical interpretation for improved clinical management. 
5.3.  BRCA1/2 scoring algorithms and founder/recurrent mutation testing 
The Manchester Scoring System was established on empirical information collected from the 
Manchester mutation screening programme. The purpose of the score is to restrict BRCA1/2 testing to 
breast and ovarian cancer patients with the highest likelihood of carrying a pathogenic mutation, which 
in turn can be used for pre-symptomatic diagnosis in at-risk family members (Evans et al. 2004). 
Characteristics such as the number of affected family members and age of onset are given a score and 
these are added together to give a combined score for each of BRCA1 and BRCA2 regarding mutation 
detection probability. This total can be converted into a percentage chance of detecting a mutation in a 
single family member affected by breast or ovarian cancer (Evans et al. 2017). The updated pathology-
adjusted Manchester score provides a valuable tool for estimation of the threshold for BRCA1/2 
probability. In unaffected family members, a 20-point score obtained in their affected first-line relatives 
indicate suitability at the 10% threshold for a positive BRCA1/2 result. The individual Manchester 
scores calculated for the five South African patients with the pathogenic BRCA2 c.7934delG variant 
resulted in scores lower than 10 in four patients, including the index case who had no family history of 
cancer. Only one patient had a high score of 26 translating into a more than 10% chance that the patient 
has a BRCA1/2 mutation, as previously shown at another laboratory prior to participation in this study.  
In order for the Manchester scoring system to be more effective in the South African population, the 
inclusion of ancestry/founder mutation status might enhance the prediction of a BRCA1/2 variant in an 
affected individual/family as evident from our results. In the South African population, at least eight 
BRCA1/2 founder/recurrent mutations associated with development of the hereditary breast and ovarian 
cancer syndrome (HBOCS) were identified previously. In a study performed by Seymour et al. (2016) 
to determine the frequency of the three most common Afrikaner founder/recurrent mutations compared 
to non-founder pathogenic variants, testing for founder/recurrent mutations was recommended first, 
before further investigation or testing of other variants in cancer patients. These authors also reported 
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that the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm 
(BOADICEA) was valuable for categorizing individuals at high risk for a BRCA1/2 mutation and also 
helped with the decision for further testing.  
The use of screening algorithms such as the Manchester score and BOADICEA, followed by genetic 
testing of a limited number of well-defined pathogenic variants present at an increased frequency in a 
given population due to a founder/recurrent effect, has traditionally been considered the most cost-
effective way to perform genetic testing, before embarking on extended genetic testing in genetically 
uncharacterized patients. Recent use of a Markov model to compare the cost-effectiveness of 
population-based BRCA1/2 testing with a clinical-criteria driven approach in Sephardi Jewish women 
based on breast/ovarian cancer outcome and excess deaths from heart disease supports the former 
approach, regardless of Ashkenazi/Sephardi ancestry (Patel et al. 2018). However, this dogma is 
increasingly challenged as the cost of NGS technologies decreases (Manchanda et al. 2018). According 
to Slade et al. (2016) when evaluating familial cancer screening in the UK, the most effective service 
approach was to screen at risk family members of cancer patients with pathogenic BRCA1/2 variants 
detected by comprehensive screening of the index case unselected by age of onset or family history. 
The information gathered in the study was assessed over a 6-month period in comparison with patient-
level data from the Royal Marsden Cancer Genetics audit, with testing offered to persons at ≥10% risk 
of having a pathogenic BRCA1/2 variant. Approximately 40% of women who utilized the Cancer 
Genetics Service through the audit had breast and/ or ovarian cancer, although 62 % of unaffected 
women were worried about their family history. Application of a structured service strategy as an 
integral part of clinical oncology might be accomplished by including germline analysis with tumour 
pathology examination. Such integration with oncology practice was regarded most time-efficient with 
better delivery of equity of access to BRCA1/2 screening than the standard highly selective service 
model based largely on family history and age of disease onset.  
There is a lack of readily available reference costs for different methodologies used for BRCA1/2 testing 
as a stand-alone test or as part of a clinical management algorithm in African countries. Analysis of 
breast cancer patients selected by the MPA in this study was the first step towards a risk-benefit analysis 
of combining the MammaPrint tumour gene profiling test with germline BRCA1/2 and CYP2D6 
pharmacogenetics. 
5.4. Incorporation of BRCA1/2 POC testing into the MammaPrint care pathway 
Numerous genetic risk-prediction models use a comprehensive approach that includes assessment of  
tumour pathology data (Evans et al. 2009, Tai et al. 2008). Some literature suggests using specified age 
pathological information in the risk prediction models might provide more precise mutation carrier 
prediction. Moreover, accurate classification of the distribution of tumour features in mutation carriers 
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might guide treatment strategies (Mavaddat et al.  2010). The National Comprehensive Cancer Network 
(NCCN) has established an all-inclusive set of clinical practice strategies to assist health providers in 
managing cancer patients. These endorsements require that any patient diagnosed with breast cancer or 
primary peritoneal/epithelial ovarian or fallopian tube cancer diagnosed, at or before the age of 50, must 
be referred for a genetic risk evaluation (Morgan et al. 2016). Genetic testing offers numerous benefits 
for women and their close family members, while genetic counselling helps patients make choices about 
their health and available therapies to improve understanding of cancer genetics (Schwartz et al. 2004). 
BRCA1/2 mutation carriers might benefit from a prophylactic surgical procedure, use of 
chemoprevention as well as regular monitoring (Rebbeck et al. 2009). Adhering to recommendations 
improved after genetic testing and counselling (Burton-Chase et al. 2013), but despite patients’ interest 
genetic counselling and testing endorsements have not been entirely incorporated into clinical practice. 
Since genetic testing could decrease deaths from breast and gynaecologic cancers, development of tools 
that can enable comprehensive cancer risk evaluations are important to make sure women with the 
disease are receiving proper treatment and care (Febbraro et al. 2015).  
The rapid POC assay used in this study was developed based on previous identification of relatively 
common BRCA1/2 founder/recurrent mutations in both tumour and germline DNA across ethnic groups 
in South Africa. This ParaDNA Screening System uses a disposable sample collector to convey the test 
material into the PCR consumable containing the pre-loaded reaction assay mix. DNA amplification 
with fluorescent HyBeacon probe detection of PCR amplicons was used to identify the target DNA 
sequences for eight BRCA1/2 founder/recurrent mutations. Changes in fluorescence occurred as the 
HyBeacon probe melts away from an amplified allele at a specific temperature, ranging between 20-
70oC. This temperature variation correlates to a proportion of fluorescence as interpreted by the software 
and converted into colour-coded identification of the targeted DNA sequences.  Standardisation of the 
POC assay employing multiplex PCR was first developed using the CFX96 Real-Time PCR detection 
system (Bio-Rad, Hemel Hempstead, UK), followed by transfer to the ParaDNA format. The ParaDNA 
BRCA 1.0 Research Assay comprises HyBeacon assays designed to simultaneously detect the 
founder/recurrent mutations in the BRCA1 and BRCA2 genes. DNA samples were genotyped using a 3-
colour, 4-tube multiplex test for the BRCA1/2 founder/recurrent mutations, which were accurately 
detected using melting curve analysis. Extracted DNAs can be manually added to each of the four plate 
wells or ParaDNA sample collectors (Blackman et al. 2015) used to transfer cells and DNA from buccal 
swabs to all plate wells simultaneously. The ParaDNA sample collectors or use of a drop of blood 
(diluted in water) allows immediate genetic testing of individual samples at or near the POC, without 
the not need to wait for DNA extraction or batching of samples for cost-effective genotyping on high-
throughput laboratory-based apparatus. The test duration from sample-to-result is approximately 60 
minutes and can provide same-day results in a clinic or a laboratory with relatively small numbers of 
samples received per day for a specific test.   
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POC testing using the ParaDNA platform has been exemplified by genotype guided dosing for warfarin, 
incorporating clinical and genetic factors to maintain the international normalised ratio within a 
therapeutic range (Jorgensen et al. 2019). Smooth implementation into routine clinical practice could 
be demonstrated, confirming the findings of a previous randomised controlled trial with a positive risk-
benefit outcome in daily practice. Only minor adjustments were suggested by staff and patients who 
trusted the results obtained in clinical management as it was verified against standard real-time PCR 
including negative controls and duplicate samples with every run. We compared our results with 
alternative methods based on available genetic reports from other laboratories for a subset of patients, 
Sanger or NGS. Relevance of the Warfarin dosing POC kit to breast cancer was furthermore evident in 
at least one South African patient included in this study, who reported deep vein thrombosis (DVT) 
ascribed to hormone therapy. This could be explained by detection of the most common genetic risk 
factor for inherited thrombophilia (factor V Leiden mutation) routinely included in the CVD multigene 
assay illustrated in Figure 1. PSGT takes advantage of both founder/recurrent and pleiotropic gene 
effects to identify genetic variants in common pathways influencing multiple cancers and/or associated 
co-morbidities (Kotze 2016). Patients referred for the MammaPrint test who are at risk of therapy-
induced comorbidities such as DVT, may therefore also benefit from Warfarin pharmacogenetics at or 
near the POC. Immobility peri-operatively and several anti-cancer therapies interact with genetic risk 
factors shared by cancer and associated co-morbidities. A multi-disciplinary approach may help to 
determine whether further testing using WES or other advanced technologies is necessary in patients 
with treatment failure, medication side-effects or co-morbidities that are not explained by the results of 
first-line POC assays.  
Pharmacogenomics is undoubtedly one area of personalized medicine with proven clinical utility in the 
areas of cancer treatment and drug safety (Pirmohamed et al.  2014).  Several translational research 
studies are focused on the introduction of pharmacogenetic analysis into clinical settings, targeting 
specific well-characterised genes such as CYP2C19 for antiplatelet treatment (Empey et al. 2018, 
Cavallari et al. 2018) and CYP2D6 genotyping for more than 20% of commonly prescribed drugs 
(Cavallari et al. 2019).   
5.5.  BRCA2 c.7934delG and CYP2D6 pharmacogenetics  
The 70 genes included in the MammaPrint assay does not analyse genes such as BRCA1/2 associated 
with development of familial breast cancer, or pharmacogenetic markers such as CYP2D6 that may 
assist with the choice of endocrine treatment between Tamoxifen or aromatase inhibitors. Patients with 
two null alleles for CYP2D6*4 or other null/reduced function variants in this gene are defined as poor 
metabolizers, while heterozygotes could be considered as intermediate metabolizers. In women 
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receiving adjuvant Tamoxifen treatment for familial breast cancer, Newman et al. (2008) showed that 
variation in the CYP2D6 gene had a significant negative effect on overall survival in patients with 
pathogenic BRCA2 variants which was not evident in BRCA1 mutation carriers.  This finding is of 
particular relevance in the South African population due to a founder/recurrent effect responsible for 
the increased BRCA/2 mutation frequency as seen in this study, especially in hormone receptor-positive 
breast cancer patients using certain antidepressants that may inhibit CYP2D6 enzyme activity (van der 
Merwe et al. 2012a).  
Confirmation of the pathogenic BRCA2 c.7934delG variant in germline DNA of the index case after 
initial detection of this variant in DNA extracted from her bladder cancer biopsy, provided a likely 
explanation for development of a second cancer despite a MammaPrint low risk profile for breast cancer 
recurrence reported earlier. Detection of CYP2D6*4 also confirmed in her germline DNA may 
furthermore explain the failure of Tamoxifen to prevent a second primary in this patient.  The value of 
PSGT lies in the integration of results from multiple assays on the same platform, which started in the 
index case with referral for the MammaPrint test. Subsequently NGS of her tumour DNA identified 
eligibility for a PARP inhibitor and could explain failure of previous drugs used. If tumour sequencing 
was not performed first, this patient’s familial risk would also not have been identified. Several studies 
have recently highlighted BRCA2 as a potential predisposition gene for urothelial carcinoma (Nassar et 
al. 2019) that can predict the prognosis of bladder cancer (Kuang et al. 2019). These findings and the 
good response to Olaparib in BRCA2-altered urothelial carcinoma after chemotherapy and PD-L1 
inhibitor failure highlight the potential benefit of BRCA1/2 screening informed by intrinsic breast cancer 
subtype (Necchi et al. 2018). 
The future of innovative technology development in the health care sector rests on consulting with 
health care professionals and understanding the challenges they are facing. By performing a clinical 
needs assessment, solutions can be developed to fill clinical gaps in disease management and treatment 
pathways. For this reason, prior to the introduction of POC DNA testing and genome sequencing 
training at a skills development workshop at the Tygerberg Academic Hospital (26-27 September 2019), 
a survey was performed at a pre-conference workshop of the Southern Africa Society of Human 
Genetics in Cape Town (August 2019). Questions were intended to assess the opinions of workshop 
participants consisting of medical scientists, genetic counsellors and treating clinicians. Results of the 
survey were published on the website of the Open Genome Project 
(https://www.gknowmix.org/opengenome/survey/), an initiative aimed at implementation of 
personalised medicine using an integrated service and research approach.  
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Of particular relevance to this study was that a large percentage of survey respondents (88%) who 
agreed with the potential benefits a pharmacogenetic POC test for CYP2D6 genotyping may bring to 
identify increased risk for Tamoxifen resistance and potential interaction with anti-depressants, as well 
as Warfarin dosing (72%) already validated in the UK. Most respondents agreed (75%) that POC testing 
for BRCA1/2 founder/recurrent mutations could augment the initiation of FDA approved PARP 
inhibitors for the treatment of hereditary breast and ovarian cancers.  
Respondents to the survey were mostly supportive of a POC test which was affordable and could be 
used for intervention in the clinical care pathway as well as during genetic counselling (>90%), but that 
screening for founder/recurrent mutations should be led by taking ancestry and family history into 
account (78%). When patients cannot afford comprehensive panel gene testing, inexpensive POC 
founder/recurrent mutation testing would suffice (91%) if genetic counsellors, knowing the limitations 
of population based testing, would interpret the findings or refer patients for sequencing when the result 
is uninformative (94%).  This approach where POCT for founder/recurrent variants followed by 
MinION or whole genome sequencing is implemented, would reduce the likelihood of missing those at 
risk of HBOC (78%), which may then be confirmed by Sanger sequencing (91%).  Some respondents 
were of the opinion that receiving a mutation positive BRCA1/2 POC testing results within an hour may 
be overwhelming for the unprepared patient (81%), as conventional testing provides time to mentally 
prepare for results (84%). Less respondents felt that providing the report after initiation of therapy 
defeats the purpose of genetic testing (34%), while most agreed (88%) that when patients need to pay 
for genetic testing themselves, they prefer more comprehensive gene panels rather than having another 
test later.  
Although only 44% of workshop respondents were concerned that a population-specific POC test would 
not be clinically useful in a diverse population where reduced detection of BRCA1/2 founder variants 
may occur over time, as well as infrequent requests for this testing in the private health care sector 
(66%), these analyses are still used as first line testing in the state sector where POCT could be widely 
utilised (75%). Where indication for BRCA1/2 founder/recurrent mutation testing is uncertain due to 
lack of family history, some respondents (47%) felt that POCT could be used to detect cases of Lynch 
syndrome. Most respondents  (84%) agreed that POCT is exciting and worth offering to other conditions 
where causative mutations are known such as in paediatric conditions, especially metabolic disorders 
where immediate treatment is lifesaving (88%).   
In our study, a founder/recurrent BRCA2 germline mutation was confirmed subsequent to tumour 
genomic identification, which supports incorporating appropriate POC BRCA DNA testing in oncology 
practice. This may benefit not only therapeutic decision making, but could present the opportunity for 
initiating cancer prevention strategies in affected family members (Veyseh et al. 2018). Careful 
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consideration is required about the level of expertise/qualification needed to perform and interpret the 
results obtained from germline DNA POC tests. Using moderately complex POCT, trained non-
healthcare, non-medical staff are capable of generating similar results to those obtained by the 
laboratory (Laney et al. 2019). If maintaining strict quality assurance, nurses may be able to perform 
POC HIV testing as well as medical technicians (Gouws et al. 2016). These studies support the 
introduction and operation of routine pathology POC tests, but are not clear as to who should operate, 
interpret and report on results obtained from POC germline tests. As POC tests are designed to be 
operated easily with low technical requirements, a wide range of users have access to them with low 
error rates. However, some studies have highlighted user errors which when assessed, held no 
significant negative impact on patient health (O’Kane et al. 2011). However, this may not be the case 
in germline POC testing, where these errors may not be as negligible and could result in serious 
physiological trauma, unwarranted risk-reducing surgery or treatment with ineffective 
chemotherapeutic agents. It therefore becomes imperative that germline POC tests are performed and 
interpreted by medically trained operators on validated testing platforms with sufficient training and 
support, who will perform the assay according to the manufacturer’s instructions under an established 
quality system. In South Africa, the SA Health Products Regulatory Authority (SAHPRA) is the 
statutory regulatory authority which replaced the Medicines Control Council for registration of in vitro 
diagnostics (IVDs), which covers POCT based on verification of registration in other countries or by 
the World Health Organisation.   
5.6. Limitations and strengths 
The small sample size and lack of direct comparison using Sanger sequencing or NGS in all 50 samples 
tested due to cost implications, were the major limitations of the study. With each new batch of BRCA 
POC kits to be manufactured in South Africa in future, at least ten control samples should be tested 
every time  to first verify the accuracy of the assay, as described in the Results section. Similar to Sanger 
sequencing currently used in our laboratory to detect or confirm known pathogenic variants detected by 
NGS, it is not possible to include positive and negative controls when patient samples are screened 
using Hybeacon probes for POC testing on the ParaDNA apparatus. Failure of one of the 50 samples 
selected from the biobank for inclusion in this study alerted us to the need for improved quality 
assurance regarding the use of stored DNA samples.  None of the results obtained in this study using 
the BRCA 1.0 Research Assay was reported back to clinicians or patients. 
Detection of the same pathogenic BRCA2 c.7934delG founder/recurrent variant among both 
MammaPrint high- and low-risk cases justifies further investigation in a larger study cohort. 
Stratification of patients with different tumour characteristics according to BRCA1/2 status may identify 
modifier genes and environmental factors underlying differences in tumour pathology associated with 
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the same founder/recurrent mutation. Incorporation of BRCA1/2  POC testing and genetic counselling 
into the MammaPrint care pathway may empower patients in high-risk populations with knowledge on 
the difference between tumour and germline genetics. Although ethnicity was not used to select the 
study cohort, the relatively high frequency of the BRCA2 c.7934delG variant may relate to the fact that 
it is the most common founder mutation in the Afrikaner population of European descent. 
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Chapter 6 
Conclusion 
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This study demonstrated that use of the MammaPrint prescreen algorithm (MPA) may identify patients 
who could benefit from pharmaco-diagnostic BRCA1/2 screening at the point-of-care  (POC), coupled 
with CYP2D6 genotyping when tamoxifen is considered for endocrine treatment.  Three of the patients 
with the same BRCA2 founder/recurrent variant were also heterozygous for CYP2D6*4 associated with 
an increased risk of tamoxifen resistance, an especially important consideration in patients with familial 
breast cancer (Newman et al. 2008). Two of these patients had a high risk MammaPrint profile and one 
a low-risk profile. Delayed detection of the cumulative risk scenario in the latter patient (index case) 
treated with tamoxifen for breast cancer, was a missed opportunity for preventing the onset of bladder 
cancer, which caused her death approximately four years after receiving a low-risk Mammaprint result. 
The histopatholgy results ruled out the possibility that development of bladder cancer in this patient 
was a result of risk misclassification using the Mammaprint test. Based on the literature, it is more likely 
that the defective BRCA2 pathway represents a genetic link between breast and bladder cancer. Absence 
of a family history of cancer or other strong clinical indicators for BRCA1/2 testing at the time of the 
MammaPrint test was performed, highlighted the importance of unrestricted screening of genes with 
pleiotropic function underpinning different forms of cancer. The unique genetic structure of the South 
African population makes cost-effective POC testing feasible as a first-line screening test towards 
comprehensive genome sequencing targeted at prevention of combined BRCA/2 -  CYP2D6 effects. 
The benefit of point-of-care  technology (POCT) is that it provides quick access to potentially actionable 
information due to relative simplicity and wide accessibility to non-medical laboratory trained 
operators, especially valued in resource-limited settings. Generally, POC tests are of low complexity, 
for example urine dipsticks or pregnancy tests, while others such as disposable single-use tests for 
glucose are of medium complexity and can be performed by the patients themselves. The results of the 
BRCA POC assay used in this study should, however, be handled with extreme caution according to 
international genetic counselling guidelines. Despite the obvious advantages of BRCA1/2 testing at the 
POC, a positive germline result has major consequences for both the patient and the extended family. 
In order to understand this issue, patients need time to discuss different clinical scenarios with educated 
healthcare workers. They need to disseminate and understand the information themselves before 
providing informed consent for BRCA1/2 testing. Given the psychological burden of being a mutation 
carrier, the cost-effectiveness and accessibility of POC does not justify implementation outside a 
clinical setting. Up to four samples can be analysed in the 4-unit ParaDNA device, while multiple 
analytes as well as nucleic acid-based POC tests can be run simultaneously in new generation pocket-
size sequencing devices such as the the MinION.  
Selection of a test system should be based on intended clinical use and evaluated accordingly. Failure 
to place  novel POCT in the clinical management care pathway is often due to the lack of clinical utility, 
possible suboptimal analytical or clinical validity, or due to a disconnect between the developer and the 
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needs of the test operator. The advantage of the ParaDNA POCT used in this study in relation to all 
three these aspects, became evident when the time needed to perform it and cost of DNA sequencing 
was considered for direct comparison of the BRCA 1.0 POC results obtained in all 50 samples analysed. 
This POC assay is considered suitable for evaluation in parallel with usual care to determine its true 
analytical and clinical validity.  
Our finding that at least one of the South African BRCA1/2 founder/recurrent mutations occurred in 
approximately 10% of hormone receptor-positive breast cancer patients, unselected for family history 
or age at diagnosis, warrants a pharmaco-diagnostic implementation study at the POC. Assessment of 
BRCA1/2 founder/recurrent mutation status, alongside routine IHC assessment of ER, PR and HER2 
status to approximate the luminal A, luminal B, HER2-enriched and basal molecular subtypes, could 
be performed during the time it takes to perform genetic counselling of patients considering Tamoxifen 
or gene-targeted therapies following MammaPrint gene profiling. Comprehensive assessment of 
recurrence risk in relation to both familial and therapy-related genetic risk factors on a single platform 
using PSGT, has the potential to translate into real-life clinical application of personalised genomic 
medicine.  
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The Health Research Ethics Committee reviews research involving human subjects conducted or supported by the Department of 
Health and Human Services, or other federal departments or agencies that apply the Federal Policy for the Protection of Human 
Subjects to such research (United States Code of Federal Regulations Title 45 Part 46); and/or clinical investigations regulated by 
the Food and Drug Administration (FDA) of the Department of Health and Human Services.Yours sincerely, 
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APPENDIX 3 
ETHICS RENEWAL 
 
 
 
HEALTH AND WELLNESS SCIENCES RESEARCH ETHICS COMMITTEE (HW-REC) 
Registration Number NHREC: REC- 230408-014 
 
P.O. Box 1906 • Bellville 7535 South 
Africa Symphony Road Bellville 7535 
Tel: +27 21 959 6917 
Email: sethn@cput.ac.za 
16 August 2019 
REC Approval Reference 
No: CPUT/HW-REC 
2018/H10 (renewal) 
Dear Mr Lwando Mampunye 
 
Re: APPLICATION TO THE HW-REC FOR ETHICS CLEARANCE 
Approval was granted by the Health and Wellness Sciences-REC to Mr Mampunye for ethical clearance on 29 
March 2018. This approval is for research activities related to student research in the Department of Biomedical 
Technology at this Institution. 
TITLE: MammaPrint risk score distribution in breast cancer patients with BRCA1/2 mutations. 
Supervisor: Dr K. Grant and Prof M.J Kotze 
Comment: 
Approval will not extend beyond 17 August 2020. An extension should be applied for 6 weeks 
before this expiry date should data collection and use/analysis of data, information and/or samples for 
this study continue beyond this date. 
 
The investigator(s) should understand the ethical conditions under which they are authorized to carry out this 
study and they should be compliant to these conditions. It is required that the investigator(s) complete an 
annual progress report that should be submitted to the HWS-REC in December of that particular year, for 
the HWS-REC to be kept informed of the progress and of any problems you may have encountered. 
 
Kind Regards 
 
 
 
Dr. Navindhra Naidoo 
Chairperson – Research Ethics Committee 
Faculty of Health and Wellness Sciences 
 
 
 
